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The first part of this dissertation assessed factors regulating the insulin sensitizing 
hormone adiponectin in dairy cows. Plasma adiponectin is reduced during the transition 
from late pregnancy (LP) to early lactation (EL) in parallel with rapid changes in the 
plasma concentration of metabolic hormones [i.e. insulin, leptin, and growth hormone 
(GH)] and non-esterified fatty acids (NEFA). The first study of this dissertation showed 
that none of these factors contribute to the regulation of plasma adiponectin. The second 
study tested the possibility that altered endoplasmic reticulum (ER) chaperone expression 
is involved. This was motivated by the following observations: 1) Plasma adiponectin 
variation in transition dairy cows occurs in absence of changes in adiponectin mRNA. 2) 
In rodents, the master regulator of ER homeostasis x-box binding protein 1 (Xbp1) 
regulates adiponectin production by increasing ER chaperone expression. We showed 
that Xbp1 expression decreased from LP to EL in the dairy cow. Using a primary bovine 
adipocyte system, overexpression of Xbp1 had no effect on adiponectin, despite 
increasing expression of several ER chaperone proteins. The factors regulating plasma 
adiponectin in the transition dairy cow remain unknown. 
The second part of this dissertation addressed the role of sel-1 suppressor of lin-
12-like protein (Sel1l) in lipid metabolism. Sel1l is a critical component of the 
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endoplasmic reticulum associated degradation (ERAD) system required for translocation 
and degradation of misfolded or aggregated proteins. Adipose-specific deletion of Sel1l 
in mice has implicated an ERAD-independent role for Sel1l in lipid metabolism. To this 
end, we generated liver-specific Sel1l knockout mice (ΔSel1lLiver) to assess whether Sel1l 
plays a similar role in lipid homeostasis in liver. Lipid metabolism was nearly normal in 
ΔSel1lLiver mice fed chow or high fat diet. ΔSel1lLiver mice on an atherogenic diet (AD) 
showed increased hyperlipidemia, hypercholesterolemia, liver damage, and occasional 
death compared to wildtype (WT) mice. This phenotype was associated with increased 3-
hydroxy-3-methylglutaryl-CoA reductase (Hmgcr) and decreased low-density lipoprotein 
receptor (Ldlr) in liver of ΔSel1lLiver mice. Together, our results reveal a previously 
unknown role for Sel1l in lipid homeostasis in liver, but further studies are needed to 
elucidate the mechanism. 
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INTRODUCTION 
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Part I: Adiponectin 
The productivity and profitability of the modern dairy cow is largely dependent 
on the efficiency of adaptation to the metabolic challenges associated with the transition 
period between late pregnancy (LP) and early lactation (EL). At the onset of lactation in 
high-yielding dairy cows, energy requirements rise nearly 4-fold in order to meet the 
demands for milk synthesis 1. Feed intake alone is not sufficient to meet the sudden 
increased nutritional demands of the mammary gland in EL, resulting in major deficits in 
virtually all major classes of organic nutrients including the lactose precursor glucose 1. 
Dairy cows cope with this nutritional insufficiency through a growing insulin resistance 
(IR) in the transition period 1. IR facilitates the use of glucose by the mammary gland 
after parturition, 1. However, excessive IR due to over-nutrition during the dry period 
and/or excessive fatness at parturition 2,3 can lead to the development of an array of 
metabolic diseases. For example, excessive plasma non-esterified fatty acids (NEFA) has 
been associated with inefficient utilization of lipid and protein reserves, loss of milk 
production, and increased susceptibility to several metabolic diseases (e.g. ketosis, 
metritis, mastitis) 4–6. Mechanisms regulating IR in transition dairy cows remain ill-
defined. Growth hormone (GH) may be involved, due to its ability to suppress insulin-
stimulated glucose uptake in adipose tissue and skeletal muscle 1. One hormone, 
however, that has not been extensively studied in the context of IR regulation in 
transition dairy cows is adiponectin. Adiponectin may be relevant to the regulation of the 
IR state in dairy cows, because it was previously implicated as an insulin sensitizer in 
rodents and humans 7,8. Moreover, the plasma concentration of adiponectin drops in 
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parallel with the rise of IR in transition dairy cows 9–11. Factors regulating the 
periparturient drop of plasma adiponectin in dairy cows are unknown. 
In the first part of this thesis, I will review the literature pertaining to adiponectin 
function and focus primarily on factors regulating its production and secretion from white 
adipose tissue (WAT). I will then report on experiments examining the role of metabolic 
factors and hormones in regulating plasma adiponectin in transition dairy cows (Chapter 
3). Second, I will report on experiments used to determine whether variation of 
endoplasmic reticulum (ER) chaperones could explain changes in adiponectin production. 
ER chaperones may be important, because adiponectin must be assembled into oligomers 
in the ER before secretion (Chapter 4). 
 
Part II: Sel1 
Hepatocytes carry out a myriad of functions involving the ER including 
triglyceride synthesis, lipoprotein assembly, and plasma protein synthesis and secretion 
12. For example, approximately 75% of all proteins destined for secretion are synthesized 
within the ER 13. Preserving ER homeostasis is critical for maintaining the biosynthetic 
capacity of highly secretory cells such as the hepatocyte.  
Imbalances in these pathways due to high demand for protein synthesis and 
secretion can enhance protein misfolding and impair ER-folding machinery function. 
These disruptions of ER homeostasis lead to the accumulation of improperly folded or 
aggregated proteins and the development of ER stress 14,15. Adaptive mechanisms 
including the endoplasmic reticulum associated degradation (ERAD) system are activated 
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in order to cope with increased ER stress 16. ERAD is a highly conserved system that 
aims to promote cell survival by eliminating aggregated and misfolded proteins 15,17,18. 
 Sel-1 suppressor of lin-12-like protein (Sel1l) is an 89-kDa transmembrane 
protein that nucleates the ERAD complex required for translocation of misfolded or 
aggregated proteins from the ER to the cytosol for degradation 19. Sel1l expression is 
induced by ER-stress inducing agents such as tunicamycin and thapsigargin in human 
embryonic kidney 293 cells (HEK293) 20. Targeted disruption of Sel1l in transgenic mice 
leads to embryonic lethality and increased ER stress 21. These studies provide evidence of 
the critical role of Sel1l in maintaining ER homeostasis. Adipose tissue deletion of Sel1l 
in mice has demonstrated a pivotal role of Se1l in maintaining ER function and 
accumulation of triglyceride 22. However, studies assessing the role of Sel1l in lipid 
homeostasis in secretory organs such as the liver are nonexistent. 
 In the second part of this thesis, I will report on the effect of liver-specific Sel1l 
ablation on lipid metabolism (Chapter 5). 
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I. STRUCTURE 
Four independent groups identified a common 30-kDa secretory protein highly 
expressed in adipose tissue and named it Acrp30, AdipoQ, apM1 or GBP28. Acrp30 and 
AdipoQ were cloned using mouse complementary deoxynucleic acid (cDNA) through 
differential display before and after differentiation of 3T3-L1 and 3T3-F442 adipocyte 
cells, respectively 1,2. apM1 was isolated from a human adipose tissue cDNA library, 
while GBP28 was purified from human plasma 3,4. The generic name adiponectin was 
eventually accepted for this 30 kDa protein 5. Adiponectin was found to share sequence 
homology to the complement factor C1q family of proteins and structural homology with 
tumor necrosis factor α (TNFα), another adipokine highly secreted by adipocytes and 
implicated in the induction of insulin resistance (IR) 6. Adiponectin consists of an amino-
terminal signal sequence, a hypervariable region that is highly divergent between species, 
a collagenous domain, and a globular domain 7,8. 
Adiponectin circulates at around 10-50 µg/mL or ~ 0.01% of total plasma proteins 
9,10. Unlike most other circulating adipokines, adiponectin circulates as homomultimers of 
3, 6, or 18-24 units respectively known as low molecular weight (LMW ~ 67 kDa), 
medium molecular weight (MMW ~ 120 kDa), and high molecular weight (HMW > 300 
kDa) adiponectin 11,12. Freeze-etch electron microscopy of adiponectin monomers 
revealed a ball and stick-like structure, while analysis of HMW adiponectin by dynamic 
light scattering and transmission electron microscopy revealed an asymmetric bouquet-
like structure 13,14. Experiments utilizing purified complexes demonstrated that 
adiponectin oligomers do not interconvert once secreted in plasma 12.  
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The molecular weight distribution of plasma adiponectin varies by species and 
gender. Plasma adiponectin circulates in a 2:1 ratio of HMW and MMW oligomers in 
female mice, while it exists exclusively as the HMW oligomer in chickens and cattle 15–
17. Moreover, the number of monomers within the HMW adiponectin complex is exactly 
18 in mice and cattle, but ranges from 18-30 monomers in humans 14,17–19. Sexual 
dimorphism has also been reported for plasma adiponectin. Total adiponectin is more 
abundant in females than males in humans and mice 20–22. Moreover, HMW adiponectin 
accounts for 50% of total plasma adiponectin in women, whereas it is equally distributed 
among all complexes in men 15.  
Formation of the LMW complex is driven by hydrophobic interactions between 
globular domains of individual monomers 6. Within LMW adiponectin, the conserved 
cysteine residue in the collagenous domain is used to covalently link 2 of the 3 monomers 
6,12. The cysteine residue in the remaining monomer interacts with the free cysteine 
residue from another LMW complex, leading to the formation of MMW and HMW 
adiponectin 23. Substitution of the cysteine residue to alanine impaired formation of 
MMW and HMW adiponectin oligomers, but had no impact on LMW formation 13. 
  
II. POST-TRANSLATIONAL MODIFICATIONS 
Many studies have reported changes in plasma adiponectin in absence of mRNA 
variation. This suggests that post-translational modifications play a role in determining 
both the absolute level of plasma adiponectin as well as the adiponectin complex 
distribution 17,24. Indeed, adiponectin oligomer assembly and multimerization requires 
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extensive post-translational modifications within the endoplasmic reticulum (ER) before 
secretion 25. 
 
Hydroxylation & glycosylation 
 Wang et al made the initial discovery that adiponectin was highly hydroxylated 
and subsequently glycosylated on four proline residues (Pro39, Pro42, Pro48, and Pro86) 
and on five lysine residues (Lys28, Lys60, Lys63, Lys72, and Lys96) in bovine adiponectin 
and on several lysine residues (Lys68, Lys71, Lys80, and Lys104) in mouse adiponectin 23,26. 
These proline and lysine residues are conserved in human adiponectin 18,26.  Additional 
proline residues undergoing hydroxylation have been identified in human adiponectin 
(Pro71, Pro76, and Pro95) 18. Substituting the conserved lysine residues with alanine 
ablated hydroxylation and subsequent glycosylation, and led to impaired intracellular 
assembly and secretion of adiponectin in Cos-7 cells 23. Similar conclusions were reached 
using prolyl- and lysylhydroxylase inhibitors in human embryonic kidney 293 (HEK293) 
cells 18. These studies implicate hydroxylation and glycosylation as post-translational 
modifications important for the proper assembly of adiponectin complexes in the 
adipocyte. 
 
ER chaperone proteins 
Proper assembly and secretion of oligomers such as adiponectin require ER 
chaperone proteins 27–31. Treatment of 3T3-L1 adipocytes with the reducing agent 2-
mercaptoethanol stimulated adiponectin secretion 28. Consistent with this finding, 
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replacement of the cysteine residue required for disulfide bond formation between 
adiponectin units exacerbated LMW adiponectin secretion in HEK293 cells 12.  
Endoplasmic reticulum protein 44 (Erp44) and Endoplasmic reticulum 
oxidoreductase 1-like α (ERO1-Lα) are two ER resident chaperone proteins induced 
during adipogenesis in 3T3-L1 adipocytes 28,29. Both have been shown to regulate the 
retention and secretion of adiponectin complexes through direct interaction with the 
highly conserved Cys39 residue 28,29. For example, Erp44 forms a mixed disulfide bond 
with the Cys39 residue of improperly assembled MMW and HMW adiponectin, thus 
preventing their secretion through thiol-mediated retention 28. Overexpressing Erp44 
expression decreased adiponectin secretion in HEK293 cells and 3T3-L1 adipocytes 28. In 
contrast, silencing Erp44 increased adiponectin secretion in 3T3-L1 adipocytes 28. ERO1-
Lα is an ER membrane-associated oxidoreductase that utilizes the oxidizing power of 
oxygen to generate disulfide bonds, which can then be transferred to substrates such as 
adiponectin through intermediate proteins [e.g. protein disulfide isomerase (PDI)] 32,33. 
Overexpressing ERO1-Lα expression increased adiponectin secretion from HEK293 cells 
and 3T3-L1 adipocytes 28. In contrast, silencing ERO1-Lα decreased adiponectin 
secretion 29.  
It has been suggested that the high affinity between ERO1-Lα and Erp44 could 
reduce the binding of adiponectin complexes by Erp44, thereby favoring adiponectin 
secretion 34. Co-expression of ERO1-Lα and Erp44 increased adiponectin secretion in 
HEK293 cells 28. Thus, Erp44 and ERO1-Lα control the maturation and abundance of 
adiponectin oligomer complexes secreted from the adipocyte.  
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Glutathione S-transferase kappa 1 (DsbA-L) is a disulfide isomerase identified as 
an adiponectin-interactive protein through a yeast two hybrid screen 30. While DsbA-L is 
expressed in a wide array of mouse tissues including liver, lungs, kidney, heart, and 
pancreas, highest expression is in adipose tissue 30.  Overexpression of DsbA-L in 3T3-
L1 adipocytes increased production and secretion of HMW adiponectin, whereas RNAi-
mediated suppression of DsbA-L reduced secretion of both total and HMW adiponectin 
into conditioned media 30. Mutating a conserved Ser16 residue in DsbA-L led to decreased 
HMW adiponectin secretion into the media in Chinese hamster ovary cells 
overexpressing the insulin receptor 30. Direct evidence of a mechanistic role of DsbA-L in 
adiponectin multimerization was obtained in genetically engineered mice 35.  DsbA-L 
overexpression in mouse adipose tissue increased HMW adiponectin in adipose tissue 
and plasma 35. In contrast, global DsbA-L knockout mice showed reduced plasma 
adiponectin 36. Confocal immunofluorescence studies showed that DsbA-L localized 
within the ER and mitochondria 37. Preventing DsbA-L translocation to the ER ablated its 
ability to increase adiponectin multimerization 37. DsbA-L therefore is an ER-associated 
protein involved in the assembly of adiponectin complexes.  
Trafficking of properly assembled adiponectin oligomer complexes through the 
trans golgi network (TGN) is dependent on golgi associated, gamma adaptin ear 
containing, ARF binding protein 1 (Gga1) - coated vesicles 31. Gga1 is a member of a 
family of ubiquitously expressed adaptor Gga coat proteins required for the proper 
sorting and trafficking of cargo proteins and vesicles through the TGN 38,39. Confocal 
microscopy and transmission electron microscopy results indicated that adiponectin co-
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localized with Gga1 in the Golgi and TGN 31. No direct interaction between adiponectin 
and Gga1 was observed in the golgi and TGN. Silencing Gga1 in 3T3-L1 adipocytes 
suppressed adiponectin secretion, whereas over-expression of Gga1 had the opposite 
effect. Similar results were obtained when wildtype (WT) or mutant Gga1 were co-
expressed with adiponectin in HEK293 cells 31. Collectively, this study shows that 
adiponectin secretion from the adipocyte is dependent on Gga1 trafficking. 
 
III. ADIPONECTIN SIGNALING 
 Two adiponectin receptors were identified through screening of a cDNA library 
derived from human skeletal muscle. These receptors are known as adiponectin receptor 
1 (AdipoR1) and adiponectin receptor 2 (AdipoR2) and have molecular weights of 42 
and 35 kDa respectively 40. Mouse AdipoR1 and AdipoR2 share 66.7% sequence 
homology and are conserved from yeast to humans 40. AdipoR1 and AdipoR2 were 
identified as integral membrane proteins featuring 7 transmembrane domains, but 
exhibiting inverse topology to G-protein coupled receptor proteins i.e. C-terminus 
external and N-terminus internal to the cell membrane 40–42. While AdipoR1 and 
AdipoR2 are ubiquitously expressed, AdipoR1 is most abundantly expressed in skeletal 
muscle, while AdipoR2 is most abundantly expressed in the liver 40.  
AdipoR1 signaling is primarily mediated through adenosine monophosphate-
activated protein kinase (AMPK), whereas AdipoR2 signaling is mediated through 
activation of peroxisome proliferator-activated receptor α (PPARα) by p38 mitogen-
activated protein kinase (p38 MAPK) 43,44. Recombinant adiponectin induced 
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phosphorylation of AMPK and p38 MAPK in C2C12 myocytes and hepatocytes. 
Signaling events were abrogated by dominant negative (DN)-AMPK or an inhibitor of 
p38 MAPK in C2C12 myocytes 40. Adenovirus encoding AdipoR1 or AdipoR2 increased 
phosphorylation of AMPK or PPARα in liver tissue of ob/ob mice respectively 45. 
Moreover, AdipoR1 knockout (ΔAdipoR1) mice exhibited decreased AMPK signaling 
with no effect on PPARα signaling in liver tissue, while AdipoR2 knockout (ΔAdipoR2) 
mice exhibited the reciprocal results 45. Mice harboring knockouts of both receptors 
(ΔAdipoR1; ΔAdipoR2) displayed defects in both AMPK and PPARα signaling in liver 
tissue 45.  
Use of the cytoplasmic domain of AdipoR1 as bait in a yeast two-hybrid assay led 
to the identification of amyloid precursor protein-like 1 (APPL1) as a receptor interacting 
protein. APPL1 is a pleckstrin homology domain protein expressed in several mouse 
tissues including brain, heart, fat muscle, skeletal muscle, spleen, kidney, and pancreas 46. 
APPL1 co-localized with adiponectin as shown through confocal microscopy in C2C12 
myocytes 46. In addition, the C-terminus and N-terminus of AdipoR1 directly interacted 
with adiponectin and APPL, respectively 46. RNAi-mediated suppression of APPL1 
decreased adiponectin signaling, whereas overexpression induced the opposite effect 46. 
 
IV. FACTORS REGULATING ADIPONECTIN PRODUCTION 
Obesity and energy overconsumption 
Excessive energy intake and adiposity are two factors associated with reductions 
in adiponectin mRNA in adipose tissue and plasma adiponectin 47,48. Plasma adiponectin 
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levels were significantly lower in obese subjects and animals when compared to controls 
2,5. Reciprocally, weight loss following gastric bypass surgery caused a significant rise in 
adipose adiponectin mRNA and plasma adiponectin 49–51. Obese diabetic patients that 
underwent weight reduction were also characterized by increased plasma adiponectin 
levels 52. In contrast, one study reported that reduced adiposity resulting from exercise 
did not lead to an increase in plasma adiponectin 53.  
Qiao et al studied the effects of either a normal chow diet or high fat diet (HFD) 
on adiponectin in the mouse 54. Plasma adiponectin did not differ when diets were fed on 
an isocaloric basis. On the other hand, adiponectin mRNA and plasma levels were 
elevated upon caloric restriction, irrespective of diets. Time-dependent rises in mRNA 
and plasma adiponectin levels were observed in calorie-restricted ob/ob mice when 
compared to WT controls 54. Moreover, only the HMW adiponectin isoform increased in 
abundance upon caloric restriction 55. Overall, these data suggest that energy intake, but 
not dietary fat regulates production and secretion of HMW plasma adiponectin.  
 
Exercise 
Acute exercise has been associated with improved insulin action 56. Reports 
pertaining to acute exercise and adiponectin have produced inconsistent results. Acute 
exercise had no effect on plasma adiponectin in healthy and obese individuals in some 
studies, whereas it increased plasma adiponectin levels in other studies 57–62. Effects of 
acute exercise on adiponectin oligomers have also been contradictory 63,64. These 
inconsistencies could be due to several factors such as the overall health of subjects 
	   17	  
(trained vs. not trained; lean vs. obese), type of exercise (cycling, running, rowing), 
measurement time points, and insufficient time required for changes in hormonal 
adaptations.  
Chronic exercise has also been associated with improved insulin action 65. 
Inconsistent results have also been reported between chronic exercise and plasma 
adiponectin. Chronic exercise increased plasma adiponectin in obese, type 2 diabetic 
(T2D) individuals 66. Moreover, one study observed a significant increase in the ratio of 
HMW/total adiponectin upon chronic exercise in healthy and obese individuals 67.  On 
the other hand, chronic exercise had no effects on plasma adiponectin in healthy or obese 
individuals in other studies, even when leading to a reduction in adiposity 53,67–69. In 
conclusion, it is still not clear whether acute or chronic exercise play a role in the 
regulation of plasma adiponectin. 
 
Metabolic hormones 
Insulin 
Several studies have demonstrated that insulin directly alters adiponectin 
expression or secretion 70–72. Insulin treatment of cultured human adipose tissue or of the 
adipocyte cell lines T37i and 3T3-L1 increased adiponectin mRNA 71–73. Inhibition of the 
insulin-signaling pathways such as phosphoinositide-3-kinase (PI3K), mitogen-activated 
protein kinase (MAPK), or ribosomal protein S6 kinase (p70S6K) reduced adiponectin 
mRNA expression and secretion in 3T3-L1 adipocytes 72,74.  
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For unclear reasons, opposite results were obtained by another group in the same 
cell line (i.e. 3T3-L1 adipocyte). Insulin treatment of 3T3-L1 adipocytes suppressed 
adiponectin mRNA expression and secretion into the media 75. Furthermore, the 
inhibitory actions of insulin on adiponectin secretion could be rescued by either treatment 
with pharmacological inhibitors of PI3K, MAPK, or p70S6K or removal of insulin from 
the media in 3T3-L1 adipocytes 75. This latter results agrees with most of the in vivo data. 
Injection of human insulin in mice caused a significant decrease in plasma levels of 
HMW, but not LMW or MMW adiponectin 12. Transgenic mice with a deletion of the 
insulin receptor in adipose tissue showed increased plasma adiponectin levels 76. 
Moreover, human subjects with a loss of function mutation in the insulin receptor have 
increased plasma adiponectin 77 . Hyperinsulinemia induced a significant drop in plasma 
adiponectin in human subjects undergoing a hyperinsulinemic-euglycemic clamp 78. A 
significant drop in plasma HMW, but not LMW adiponectin were also observed in 
diabetic and non-diabetic subjects under hyperinsulinemic conditions 79. 
  
Growth hormone (GH) 
GH is considered an upstream regulator of adiponectin signaling as it has been 
known to antagonize insulin action 80. Treatment of cultured human adipose tissue with 
GH suppressed adiponectin secretion 81. Injection of GH or of itjs mediator, insulin-like 
growth factor-I (IGF-I), decreased plasma adiponectin in mice 82. Consistent with these 
data, mice lacking the growth hormone receptor (ΔGHR) have increased plasma 
adiponectin, despite exhibiting greater fatness 83. On the other hand, the opposite effect 
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was seen in transgenic mice overexpressing GH (Tg-GH)  81,84. Finally, the repressive 
effects of exogenous GH therapy on the HMW adiponectin oligomer were observed in 
both mice and human children 82,85. Together, these studies suggest that GH reduces 
plasma adiponectin levels.  
 
Leptin 
Some studies have suggested that leptin regulates adiponectin production and 
secretion. Human adipocytes treated with recombinant leptin expressed higher levels of 
adiponectin mRNA and produced more adiponectin; opposite results were observed when 
a leptin antagonist was used 86. Ex vivo treatment of human adipose tissue with leptin led 
to increased adiponectin mRNA and protein 86.  
Other reports suggest that leptin had no effect on adiponectin secretion. Healthy 
and obese human subjects treated with human leptin experienced no significant changes 
in plasma adiponectin 87. Plasma adiponectin was increased in obese leptin deficient 
humans subjects treated with human leptin 88. However, the latter is likely caused by the 
dramatic loss of adiposity during leptin therapy. Rats treated with recombinant leptin had 
no change in adiponectin mRNA in adipose tissue 89. In conclusion, in vitro data support 
a positive role for leptin in regulating adiponectin production, but this conclusion is not 
supported in vivo. 
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V. EVIDENCE IMPLICATING ADIPONECTIN IN THE REGULATION OF 
INSULIN ACTION 
Clinical evidence in humans and mice 
Plasma adiponectin is frequently reduced in human subjects experiencing 
conditions of diseases associated with IR. For example, plasma adiponectin is decreased 
in obese individuals when compared to lean controls 5. Plasma adiponectin was also 
reduced in conditions associated with insulin insensitivity such as T2D. This negative 
association between plasma adiponectin and insulin action has been observed across 
ethnic groups including the Japanese, African Americans, Chileans, and Asian Indians 
52,90–95. Similar trends were observed in other animals including mice, monkeys, marmots, 
and dolphins 2,96–99. 
Rodent models were used to investigate whether reduced plasma adiponectin was 
a mere consequence of obesity, IR, and T2D or if it contributed to the pathologic defects 
of these conditions. For example, mice lacking the leptin receptor (db/db) and mice 
overexpressing the agouti gene (KKAy) suffer from low adiponectin and IR. Infusion of 
adiponectin restored plasma adiponectin to levels comparable to WT mice and reversed 
IR 100. In a second independent experiment, IR was induced in heterozygous peroxisome 
proliferator-activated receptor γ (PPARγ) knockout mice by reducing PPARγ action with 
a PPARγ antagonist. Adiponectin infusion in these mice reduced plasma free fatty acid 
(FFA) and triglyceride levels in skeletal muscle and liver 100. Together, these studies 
provided evidence that adiponectin could exhibit anti-diabetic and hypolipidemic effects.  
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Freubis et al induced metabolic syndrome in WT mice by feeding a HFD. 
Administration of globular adiponectin to these mice caused a significant drop in body 
weight and plasma triglyceride, FFA, and glucose 101. Similarly, Yamauchi et al showed 
that globular adiponectin induced AMPK signaling in skeletal muscle in mice and C2C12 
myocytes 102.  This effect was not seen in C2C12 myocytes overexpressing a dominant 
negative version of AMPK. Together, these data suggest that globular adiponectin 
improves insulin action in skeletal muscle by activating the AMPK signaling pathway.    
Berg et al treated diabetic mouse models with full-length adiponectin produced in 
mammalian cells. This treatment led to improved systemic insulin sensitivity as shown by 
decreased plasma glucose levels 103.  Using the insulin clamp technique, they showed that 
adiponectin inhibited endogenous glucose production, but had no effect on peripheral 
glucose uptake 104. Consistent with these data, adiponectin decreased expression of 
enzymes involved in gluconeogenesis in liver, which included glucose-6-phosphatase and 
phosphoenolpyruvate carboxykinase 104. Collectively, these results suggest that plasma 
adiponectin increases hepatic insulin sensitivity, leading to reduced glucose production 
102–104.  
 
Genetic evidence 
Genetically engineered mouse models were developed to assess the functional 
role of adiponectin in vivo. The ability of insulin to inhibit hepatic glucose production 
was impaired in adiponectin knockout (ΔAdiponectin) mice, whereas no effects were 
observed on peripheral glucose disposal 105. Transgenic adiponectin overexpression (Tg-
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Adiponectin) mice displayed decreased hepatic glucose production, plasma glucose and 
insulin levels, and increased phosphorylation of AMPK in liver 106. More recently, Kim et 
al created an ob/ob mouse strain overexpressing adiponectin in adipose tissue (Tg-
Adiponectin; ob/ob) 107. In response to a bolus infusion of 2-deoxyglucose, these mice 
experienced a reduction in hepatic glucose output, resulting in normalization of plasma 
glucose levels, whereas this effect was not seen in ob/ob mice. The Tg-Adiponectin; 
ob/ob mice also exhibited significant improvements in hepatic insulin sensitivity as 
shown by increased phosphorylated Akt 107. Together, these studies point to the liver as a 
primary target tissue responsible for full-length adiponectin-mediated alterations in 
insulin sensitivity.  
Genetic evidence has also been obtained in humans. The adiponectin gene is 
located on chromosome 3q27, close to loci associated with metabolic diseases including 
T2D 108,109. Several mutations within the adiponectin gene have been linked to 
hypoadiponectinemia, IR, and T2D. SNP276 within intron 2 (G vs. T) was associated 
with decreased plasma adiponectin and increased IR, obesity, and T2D in Japanese, 
American, and German subjects 110–112. SNPs 11377 and 11391 in the promoter region of 
the adiponectin gene were associated with hypoadiponectinemia and T2D in French 
Caucasians 109. Two missense mutations (I164T and R112C) disrupted assembly of LMW 
adiponectin and adiponectin secretion in human subjects with the metabolic syndrome 
19,113. Similarly, G84R and G90S mutations were responsible for inhibition of the 
assembly and secretion of the HMW adiponectin 19. These results show that insufficient 
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production and secretion of adiponectin oligomers are associated with several metabolic 
diseases, including T2D. 
 
HMW adiponectin 
Additional evidence implicating adiponectin as an insulin sensitizer came from 
studies investigating whether all adiponectin isoforms were equally potent. Plasma 
abundance of HMW adiponectin was correlated with indices of insulin action, but total 
adiponectin was not 114. It was later found that increased changes in the ratio of plasma 
HMW/total adiponectin were positively correlated with increased insulin sensitivity in 
patients of T2D and gestational diabetes mellitus (GDM) 114.  
Functional assays and genetically engineered animal models were developed to 
determine whether plasma HMW adiponectin was causally involved in regulating insulin 
action. Administration of HMW, but not LMW adiponectin induced a dose-dependent 
drop in plasma glucose levels in ΔAdiponectin mice, indicating a stimulation of insulin 
sensitivity 114. To a similar extent, acute injection of HMW adiponectin in mice triggered 
the activation of downstream hepatic adiponectin signaling, while chronic infusion led to 
alleviation of hyperglycemia and IR in db/db mice 23.  In agreement with these in vivo 
data, an adiponectin variant unable to assemble into HMW isoforms was less effective 
than WT adiponectin in alleviating the hyperglycemia, hypertriglyceridemia, and IR of 
db/db mice 23. Together, these data implicate HMW adiponectin as the most potent 
oligomer capable of modulating insulin action.  
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Pharmacological evidence 
A final piece of evidence relating adiponectin to insulin action comes from studies 
of thiazolidinedione (TZD), a class of drugs known to act on PPARγ. They are used as 
therapeutics to treat IR and the metabolic syndrome. TZDs improve insulin action, 
through mechanisms that include suppression of hepatic gluconeogenesis and stimulation 
of peripheral glucose disposal 115–117. Use of TZDs led to partial correction of 
hyperglycemia and hyperinsulinemia in humans and db/db mice 2,118–120. All of these 
actions occurred in parallel with a rise in plasma adiponectin, more specifically the HMW 
oligomer 9,100,114,121. Thus, these data suggest the possibility that adiponectin mediates the 
insulin-sensitizing effects of TZDs.  
 A number of studies have focused on the molecular mechanisms accounting for 
positive effects of TZDs on adiponectin mRNA. A significant rise in adiponectin mRNA 
was reported upon treatment with TZDs 10,121. Consistent with transcriptional regulation, 
a PPARγ response element (PPRE) was identified within the human and mouse 
adiponectin promoters 70,122. PPARγ was shown to specifically bind to the PPRE in the 
human adiponectin promoter 122. Both human or mouse adiponectin promoters were 
activated in HEK293 cells co-transfected with a PPARγ expression-vector 70,122. TZD 
treatment further stimulated human and mouse adiponectin promoter activity, and these 
effects were lost when the PPRE was mutated 70,122. Together, these studies suggest that 
the positive effects of TZD on plasma adiponectin involve a stimulation of adiponectin 
transcription. 
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Functional evidence for the regulatory role of PPARγ signaling on adiponectin 
expression and secretion was observed using genetically engineered mouse models. 
Transgenic mice with a targeted deletion of PPARγ in adipose tissue (ΔPPARγAdipose) 
exhibited substantially decreased plasma adiponectin levels 123. Moreover, TZD treatment 
had no effect on insulin sensitivity in the adipose tissue of these mice. Therefore, this 
study suggested that TZDs target adipose PPARγ to increase adiponectin production and 
secretion 123.  
A series of experiments focused on whether TZDs mediate insulin sensitivity in 
an adiponectin dependent or independent manner. First, murine models of obesity 
including db/db and KKAy mice displayed significantly lower plasma adiponectin levels 
than WT mice and suffer from IR 100. Second, TZD treatment of ob/ob or db/db mice 
increased plasma adiponectin levels and improved insulin action 100,124. Third, 
overexpression of adiponectin in ob/ob mice improved insulin action 105,107. Fourth, TZD-
mediated improvements in insulin action were diminished in ob/ob mice lacking 
adiponectin 105. Collectively, these findings show that TZD-induced improvements in 
insulin sensitivity and glucose tolerance are mediated in an adiponectin-dependent 
manner. 
In many studies however, TZD increased plasma adiponectin in absence of 
increased mRNA, suggesting that post-translational effects are also involved 125,126. In 
this context, TZD has been shown to activate the transcription of the genes encoding 
DsbA-L and Erp44, two ER protein involved in the assembly of adiponectin oligomers. 
Both PPARγ agonists and PPARγ overexpression increased mRNA expression of DsbA-
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L and Erp44 in HEK293 cells and 3T3-L1 adipocytes, whereas silencing PPARγ with 
genetic or pharmacological approaches led to the opposite effect 125,126. Moreover, TZD 
treatment of HEK293 cells overexpressing PPARγ led to increased production of HMW 
adiponectin, but not MMW and LMW adiponectin, suggesting that this effect was 
through increased expression of ER-associated proteins 125,126.  
 
VI. PHYSIOLOGICAL STATE; PREGNANCY TO LACTATION 
  IR is a naturally occurring maternal adaptation of pregnancy that ensures 
adequate glucose availability to the developing fetus 127. A number of studies have 
focused on the possibility that reduced adiponectin could contribute to the onset of IR 
during pregnancy. Variation in plasma adiponectin levels during different stages of 
pregnancy has been reported in rodents and human subjects. Plasma adiponectin 
significantly dropped during late pregnancy (LP) in mice 128. On the other hand, a 
significant drop in plasma adiponectin starting from the first week of pregnancy and 
ending during lactation was observed in mice 20. In women, one group reported a 
significant drop in plasma adiponectin from the 1st to the 3rd trimester of pregnancy 129. 
Plasma adiponectin levels during lactation were comparable to 3rd trimester levels in 
women 129. Mazaki-Tovi et al, however, reported that plasma adiponectin was 
significantly lower in lactation relative to pregnancy in women 130. On the other hand, 
other studies found no significant changes in plasma adiponectin during human 
pregnancy 131. 
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 GDM is a disorder associated with IR during human pregnancy. A relationship 
was identified between low plasma adiponectin levels and increased risk of GDM 132,133. 
A number of studies observed decreased plasma adiponectin in pregnant women with 
GDM when compared to pregnant women without GDM 132–138. Furthermore, plasma 
adiponectin decreased in all three trimesters of pregnancy as well as at parturition in 
human subjects with GDM 132,133,135,138. In agreement with these results, decreased 
adiponectin was observed at parturition in women with GDM relative to healthy controls 
136.  
 
VII. THE TRANSITION PERIOD IN DAIRY COWS AS AN INSULIN-
RESISTANT STATE 
Metabolic challenges during the transition period  
The productivity and profitability of the modern dairy cow is largely dependent 
on adaptations to the metabolic challenges associated with the transition from LP to early 
lactation (EL). These adaptations have been studied during the transition period 
extending from 3 weeks before to 3 weeks after parturition 139. This period is dominated 
by parturition and the substantial increase in nutritional demands associated with milk 
synthesis 139. As the dominant precursor for lactose synthesis, glucose demand by the 
lactating mammary gland requires up to 80% of whole body glucose supply during EL 80. 
Within a few days of parturition, total energy requirements increase by 4-fold 127,140. 
Voluntary feed intake fails to increase sufficiently to cover these additional needs of the 
mammary gland during EL, leading to a state of negative energy balance (NEB) 140. Tight 
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regulation of the mobilization of endogenous lipid reserves is critical for a successful 
transition from LP to EL in the dairy cow. When excessive, dairy cows are more 
susceptible to health disorders, including ketosis, fatty liver, displaced abomasum, 
retained placenta, and ultimately decreased milk yield 141–144. Overfeeding during the dry 
period and/or excessive fatness at parturition can lead to excessive mobilization of lipid 
reserves and an exaggerated increase in plasma non-esterified fatty acid (NEFA) levels 
145–148. 
 
IR as an adaptive and maladaptive mechanism 
Mobilization of endogenous reserves is regulated through changes in plasma 
hormones and/or the ability of tissues to respond to these hormones 149. For example, 
increased adipose tissue responsiveness to catecholamines leads to increased lipolysis 150. 
Induction of an IR state in EL attenuates insulin action (i.e. stimulation of lipogenesis, 
inhibition of lipolysis, and inhibition of proteolysis) 151. As a result, FFA and glycerol are 
mobilized and provide additional precursors for adenosine triphosphate (ATP) generation 
(FFA) and hepatic gluconeogenesis (glycerol) 80,152. IR also favors glucose uptake by the 
mammary gland, because its uptake is insulin-independent 153.  In addition, 
hypoinsulinemia in EL leads to decreased insulin-mediated glucose uptake in skeletal 
muscle and adipose tissue 80,152. 
Several factors have been shown to promote IR in the periparturient period. 
Increased plasma NEFA, as a consequence of excessive fat mobilization, has been linked 
to IR in dairy cows. Increased plasma NEFA and decreased insulin-stimulated glucose 
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uptake were observed in non-pregnant, non-lactating dairy cows fasted for 4 days 154. In 
agreement, non-pregnant, non-lactating dairy cows infused with triglyceride exhibited 
increased plasma NEFA and decreased insulin action 155. 
Inflammation has been associated with IR 156. Inflammatory cytokines such as 
TNF-α are known to cause impaired insulin action in cattle 157. Whether variation in 
immune responses during the transition period promote IR in the periparturient period is 
not completely understood 158. Increased inflammation has been linked to IR in EL 159.  
GH has been known to promote IR in dairy cows 160. It does this by suppressing 
insulin-stimulated glucose uptake in adipose tissue and skeletal muscle and by decreasing 
the ability of insulin to inhibit hepatic gluconeogenesis 127,160. The antagonistic effects of 
GH on insulin action, however, have not been demonstrated during the transition period 
in dairy cows 161,162.  
Additional factors are likely involved in modulating insulin action in the 
transition dairy cow. Adiponectin is another hormone shown to modulate the effects of 
insulin in other species. It’s regulation and actions in transition dairy cows, however, has 
not been studied extensively.  
 
VIII. ADIPONECTIN DURING THE TRANSITION PERIOD IN DAIRY COWS 
 Investigation of the adiponectin system in dairy cows has been primarily focused 
on the transition period.  
Reports of plasma adiponectin regulation during the transition period have been 
relatively consistent. Plasma adiponectin varied, with highest levels during LP, a 
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maximal reduction around parturition, and a gradual rise to LP levels during the first few 
weeks of EL 17,163–167. Furthermore, adiponectin exists nearly exclusively as the HMW 
isoform in dairy cows 17. Inconsistent evidence currently exists on whether adiponectin 
mRNA is regulated during the transition period. A significant drop in adiponectin mRNA 
levels from LP to EL was found in one transition cow study 168, whereas other studies 
found no such effect 17,169,170. In particular, Saremi et al reported that adiponectin mRNA 
did not change over the first few weeks of lactation when measured in subcutaneous (tail-
head, withers, or sternum) or visceral (omental, mesenteric, and retroperitoneal) adipose 
tissue in primiparous dairy cows 170. On the other hand, adiponectin protein abundance in 
these cows was increased over the first few weeks of lactation in both subcutaneous and 
visceral (retroperitoneal, mesenterial, and omental) adipose tissue 163,164. 
Collectively, these studies illustrate effects of the transition period on adiponectin 
mRNA and protein, but do not specifically address the mechanism accounting for these 
changes. This dissertation will therefore aim to identify potential potent factors involved 
in the production and secretion of adiponectin in the modern dairy cow. 
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CHAPTER 3 
 
REDUCED PLASMA ADIPONECTIN IN TRANSITION DAIRY COWS IS NOT 
CAUSED BY CHANGING PLASMA LEPTIN, INSULIN, GROWTH HORMONE, 
OR NEFA1 
 
 
 
 
 
 
 
 
 
___________________________ 
 
1Krumm C.S., Giesy S.L., Caixeta L.S., Butler W.R., Sauerwein H., Kim J.W., and 
Boisclair Y.R. (2016) Reduced plasma adiponectin in transition dairy cows is not caused 
by changing plasma leptin, insulin, growth hormone, or NEFA. In preparation. 
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INTRODUCTION 
Adiponectin is a 30-kDa protein hormone synthesized exclusively by white 
adipose tissue (WAT) 1–3. Adiponectin circulates as a homomultimer consisting of low 
molecular weight (LMW), medium molecular weight (MMW), and high molecular 
weight (HMW) complexes containing 3, 6, or 18 or more adiponectin monomers 4. 
Adiponectin signals through two membrane bound receptors known as adiponectin 
receptor 1 (AdipoR1) and adiponectin receptor 2 (AdipoR2) found in most tissues 
including liver, muscle, and adipose tissue 5,6. Many lines of evidence suggest that 
adiponectin is an insulin sensitizer. First, decreased plasma adiponectin is observed in 
conditions and diseases characterized by insulin resistance (IR) such as obesity and type 
2 diabetes 7,8. This inverse relation between IR and plasma adiponectin has been found 
not only in humas, but also in various animal models ranging from non-human primates 
to dolphins 7,9–12. Second, administration of recombinant adiponectin improved insulin 
action in various mouse models of IR (diet-induced obese, lipoatrophic, db/db, and 
KKAy) 13. Third, mutations leading to adiponectin loss of function promote IR in both 
mice and humans 14,15, whereas adiponectin overexpression in IR ob/ob mice is sufficient 
to normalize their excessive circulating levels of glucose and insulin 16.  
We and others have demonstrated that the plasma concentration of adiponectin 
varies in a quadratic manner in transition dairy cows, with the highest levels in late 
pregnancy (LP), a nadir on the day of parturition, and a progressive return to LP values 
over the first few weeks of lactation 17,18. This adiponectin profile occurs in parallel with 
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with rapid reduction in plasma insulin and leptin and reciprocal changes in plasma 
growth hormone (GH) and non-esterified fatty acids (NEFA) 17,19,20. There is evidence in 
rodents and humans that each of these factors regulate adiponectin production 21–23, but 
whether they contribute to variation in plasma adiponectin in transition dairy cows 
remains unknown.  
The objectives of the present study were first to determine whether the onset of 
NEB around parturition contributes to reduced plasma adiponectin, and second whether 
sudden changes in the plasma concentrations of leptin, insulin, GH, or NEFA regulate 
plasma adiponectin. Our results demonstrate that plasma adiponectin is sensitive to 
changes in energy balance in the immediate post-periparturient period, but rule out leptin, 
insulin, GH, or NEFA as factors contributing to reduced plasma adiponectin in transition 
dairy cows.  
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MATERIALS & METHODS 
Animals and Design 
 Plasma samples from five previous experiments designed to identify effects of 
single metabolic or hormonal factors (energy balance, leptin, insulin, GH, and plasma 
NEFA) were used 19,24–26. All experiments were performed in multiparous Holstein cows 
at Cornell University and were approved by the Cornell Institutional Animal Care and 
Use Committee. Procedures common to all experiments included housing in individual 
stalls and blood collection from chronic intrajugular catheters. Blood was processed to 
obtain plasma following the addition of sodium heparin (15 IU/mL), and centrifugation. 
Unless otherwise mentioned, cows were fed unlimited amounts of total mixed rations 
(TMR) using automatic feeders and milked daily at 0600 and 1800 h after parturition. 
Experiments and associated specific procedures were as follows. 
 
Effect of the periparturient period and leptin 
 The first study was used to compare assays in their ability to detect changes in 
plasma adiponectin between LP and early lactation (EL) and to assess the effects of leptin 
therapy in EL 25. Ten cows were fed unlimited amounts of TMR formulated for each 
physiological stage (1.5 Mcal of net energy of lactation (NEL) and 140 g crude protein 
(CP) per kg dry matter (DM) in LP and 1.5 Mcal NEL and 180 g CP per kg DM in EL). 
Plasma adiponectin was analyzed on 4 blood samples collected at 2 h intervals between 
0800 and 1400 h in LP (day -29 ± 2, relative to parturition day 0) and again in EL (day 
+8).  After completing blood sampling on day +8, cows were randomly assigned to 
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receive a continuous intrajugular infusion of saline (Control) or human leptin (hLeptin, 
61 µg/kg body weight/day; Lilly; Indianapolis, IN) for 96 consecutive hours. Plasma 
adiponectin was measured on 4 samples taken at 2 h intervals between 88 and 94 h of 
infusion.  
 
 
 
Energy balance after parturition 
This study was used to evaluate the effect of positive energy balance in EL on the 
recovery of plasma adiponectin 19. Between parturition and day +32 of lactation, cows 
were offered a low energy TMR (1.52 Mcal NEL and 189 g CP per kg DM) and milked 
thrice daily at 0900, 1600, and 2300 h (Lactating, n = 7) or offered a high energy TMR 
(1.70 Mcal NEL and 188 g CP per kg DM) and never milked (Non-lactating, n = 7). 
Lactating cows were fed ad libitum during the first week postpartum and thereafter 
limited to amounts consumed on day +7 (13.6 ± 1.2 kg/day); non-lactating cows were fed 
ad libitum at all times. A body condition score (Thin = 1, Fat = 5) was assigned to each 
cow on week 1 and 4 by two independent individuals using the system developed by 
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Wildman et al 27. Plasma variables including adiponectin were analyzed on 4 blood 
samples collected every other day between day +5 and +11 and again between day +26 
and +32.  
 
Effect of Insulin 
This study was used to assess the effect of chronic hyperinsulinemia in LP and in 
EL on plasma adiponectin 24. Six cows were fed unlimited amounts of appropriate TMR 
during LP (1.56 Mcal NEL and 140 g CP per kg DM) and EL (1.58 Mcal NEL and 198 g 
CP per kg DM). They were subjected to the hyperinsulinemic-euglycemic clamp 
procedure starting on day -31 ±1.5 of LP and day +7 ± 1.6 of EL. The clamp procedure 
involved a 66 h period of basal blood sampling followed by infusion of bovine insulin at 
the rate of 1 µgkg body weight-1h-1 for 96 h in LP and 48 h in EL. During insulin 
infusion, plasma glucose levels were monitored every hour and maintained to the 
concentration of blood glucose observed during the basal period by varying the rate of 
infusion of glucose solution (50% wt/vol dextrose solution) 24. Plasma adiponectin was 
determined on samples collected during the basal period (-66, -43, -30, and 0 h, relative 
to initiation of insulin infusion) and on 4 plasma samples collected at 4 h intervals 
between 36 and 48 h and 84 and 96 h of hyperinsulinemia during LP, and between 36 and 
48 h of hyperinsulinemia during EL. 
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Effect of GH 
This study was used to assess the effect of chronic GH treatment in LP and EL on 
plasma adiponectin 26. Fourteen cows were offered unlimited amounts of TMR 
appropriate for each physiological stage (1.52 Mcal of NEL and 142 g of CP per kg DM 
in LP and 1.72 Mcal of NEL and 179 g of CP per kg DM in EL) over a 5-day period (n = 
7 per physiological stage). They were studied either in LP (day -40 to -36, relative to 
parturition on day 0) or EL (day +7 to +11). On the first day of each period, basal blood 
samples were collected hourly over a 3 h period, followed by biopsy of adipose tissue 
from the tail-head subcutaneous depot. Immediately after, cows received an intrajugular 
bolus of GH (20 µg rbST per kg BW; Monsanto Co; St. Louis, MO) and a second adipose 
tissue biopsy was taken 15 min later. GH treatment was continued over the next 4 days 
via intramuscular (IM) injections of 40 mg/day of rbST. The rbST dose and length of 
treatment were based on previous studies that showed effective GH bioactivity in dairy 
cows during LP and EL 28,29. Blood samples were collected at hourly intervals between 
1000 and 1300 h on the last day of treatment. Blood samples collected during the basal 
	   56	  
sampling and on day 5 of GH treatment were analyzed for plasma insulin-like growth 
factor–I (IGF-I) and adiponectin.  
 
 
Effect of NEFA  
 This study was used to assess the effects of increased plasma NEFA on plasma 
adiponectin. Six non-pregnant, non-lactating dairy cows were fed a single TMR (1.54 
Mcal NEL and 143 g CP per kg DM) in amounts covering 120% of energy requirements 
(NRC 2001) throughout the entire experiment. They were randomly assigned to two – 3 x 
3 latin squares with experimental periods of 17 h separated by 3-day intervals. Each 
experimental period included basal blood sampling over 1 h followed by a 16 h period of 
treatment. Treatments consisted of various combinations of subcutaneous (SC) injections 
of saline or bovine glucagon (Eli Lilly; Indianapolis, IN) and intravenous (IV) infusion of 
saline or 20% intralipid solution (Frasenius, Kabi; Deeriled, IL). These treatments were: 
1) IV infusion and SC injections of saline (Control); 2) IV infusion of intralipid and SC 
injection of saline (intralipid); 3) IV infusion of intralipid and (SC) injection of glucagon 
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(intralipid + glucagon). Intralipid was infused at the rate of 100 mL/hr for 16 consecutive 
hours and glucagon was administered at the dose of 5 mg at 0 and 8 h relative to the start 
of treatment. The glucagon dose and time between injections was chosen based on a 
previous study that maintained elevated glucagon concentrations over a 14-day 
experimental period in dairy cows 30. Blood samples obtained during the basal period (-1 
and -0.5 h relative to treatment at 0 h) and during treatment (0, +3, +7, +10, +13, and +16 
h) were analyzed for plasma NEFA and adiponectin.  
 
 
 
Analysis of metabolites and hormones 
Plasma NEFA were measured by the acyl-CoA synthetase/oxidase method 
described previously 31. Plasma insulin and IGF-I were measured with double-antibody 
RIA as previously described  31,32. Plasma leptin was measured with a double-antibody 
RIA capable of detecting only bovine leptin 19 or hLeptin 25 (Linco Research, Inc.; St. 
Charles, MI). Effective leptin concentration in hLeptin infused cows was calculated as 
the sum of bovine leptin and human leptin corrected for its ability to activate the bovine 
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leptin receptor 25. Inter-assay and intra-assay coefficients of variation for these assays 
averaged less than 6% and 8% respectively.  
Plasma adiponectin was measured by an indirect competitive ELISA designed to 
measure bovine adiponectin 18. The assay was performed exactly as originally described, 
except for the following modifications. The calibration curve was prepared by a 4-fold 
serial dilution of the reference serum and ranged from 0.08 to 20 ng/mL. Other 
modifications included dilution of samples (1:20,000 instead of 1:80,000), volume of 
diluted samples and standards inputted in the assay (20 µL instead of 50 µL), and dilution 
of the primary antibody (1:5,000 instead of 1:2,000). The assay was developed with 100 
µL of secondary antibody (donkey anti-rabbit HRP [Jackson ImmunoResearch #711-035-
152]; 1:15,000 dilution in assay buffer), and 100 µL substrate solution (SureBlueTM TMB 
Microwell Peroxidase Substrate; KPL; Gaithersburg, MD). The reaction was stopped by 
adding 100 uL of TMB stop solution (KPL) followed by reading of the optical density at 
450 nm with a microplate reader. Inter-assay and intra-assay coefficients of variation for 
all assays averaged less than 6.4% and 8% respectively. Plasma adiponectin was also 
measured in a subset of samples by western immunoblotting exactly as described recently 
17. In brief, plasma samples (1.5 µL of 1:10 dilution for plasma) were electrophoresed 
under reducing conditions on 13% SDS-PAGE gels and electroblotted onto nitrocellulose 
membranes (Protran, Schleicher & Schuell Bioscience; Keene, NH). The membranes 
were incubated with bovine adiponectin antiserum (1:1,000 dilution) and developed with 
a 1:2,000 dilution of IR Dye 800-nm goat anti-rabbit secondary antibody (LI-COR 
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Bitoechnology; Lincoln, NE). Signals were quantified with the LI-COR Odyssey infrared 
imaging system using the 800-nm channel. 
 
Western immunoblotting of adipose tissue extract 
Bovine adipose tissue was homogenized in 2 mL of lysis buffer [10 mM Tris, 
pH7.6, 10 mL/L Triton X-100, 1 mM EGTA, 150 mM NaCl, 1 mM Na3VO4, 1 mM Na 
pyrophosphate, 10 mM NaF, 1 mM EDTA, 1 mM phenylmethylsulfonyl fluoride 
(PMSF), 10 mg/L aprotinin, and 10 mg/L leupeptin]. Homogenates were clarified by 
centrifugation (10,000 ´ g for 20 min at 4°C). Protein concentrations of cellular extracts 
were determined using a bicinchoninic acid assay (BCA) protein assay kit (Thermo 
Fisher; Waltham, MA). Fixed amounts (55 µg) of protein extract were separated on 10% 
polyacrylamide gels and transferred onto nitrocellulose membranes (Protran, Schleicher, 
and Schuell Bioscience; Dassel, Germany). Membranes were immersed in blocking 
solution (50 mM Tris, pH 7.4, 200 mM NaCl, 1 mL/L Tween 20, 50 g/L nonfat dried 
skim milk). Membranes were then immunodecorated overnight at 4°C with a 1:4,000 
dilution of antibodies against signal transducer and activator of transcription-5 (Stat5; 
Cell Signaling; Danvers, MA) or a 1:1,000 dilution of antibodies against tyrosine 
phosphorylated Stat5 (Cell Signaling). Signals were developed with a 1:5,000 dilution of 
goat anti-rabbit antibody (Thermo Fisher; Waltham, MA) in 5% non-fat dried skim milk 
and visualized by chemiluminescence exposure to film (Super Signal West Pico 
Chemiluminescent Substrate, Thermo Fisher). Signals were quantified by densitometry 
using the NIH 1.6.3 software (National Institutes of Health; Bethesda, MD). 
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Statistical Analysis 
Data were analyzed by a mixed model using the fit model procedure of JMP Pro 
11.0 statistical software (SAS Institute; Cary, NC). Data from the periparturient period 
study were analyzed by a mixed model accounting for physiological stage (LP or EL) as 
the fixed effect and cow as the random effect. For the leptin infusion portion of the 
experiment, data were analyzed with the fixed effect of treatment (Control or hLeptin) 
and cow as the random effect with data obtained on day 8 as a covariate. For the energy 
balance study, the mixed model accounted for treatment (Lactating vs. Non-lactating), 
time (week 1 vs. 4), and their interaction as the fixed effects and animal as the random 
effect. For the insulin and GH studies, the mixed model accounted for physiological stage 
(LP vs. EL), treatment (either Basal vs. Insulin or GH), and their interaction as the fixed 
effects and animal as the random effect. For the NEFA study, the mixed model accounted 
for treatment (Saline, Intralipid, and Intralipid + Glucagon), time (0, 3, 7, 10, 13, and 16 
h), and their interaction as the fixed effects and animal as the random effect. Values 
obtained during the basal period (average of -1 and -0.5 h samples) were used as a 
covariate. Correlations between plasma adiponectin and other variables were performed 
using the fit model procedure of JMP. Statistical significance was set at P < 0.05. 
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RESULTS 
Comparison of adiponectin assays 
In previous work, we reported a 30% reduction in plasma adiponectin between 
day -35 and +7 relative to parturition on day 0 when measured by western 
immunoblotting 17. This technique has limited applicability for the analysis of numerous 
samples across multiple studies. Accordingly, we used another transition cow study to 
compare a recently developed bovine adiponectin ELISA to our western immunoblotting 
assay. Energy indicators in that study varied as expected, with energy balance and plasma 
NEFA averaging 12.1 Mcal NEL/d and 108 µM in LP and -15.2 Mcal NEL/d and 386 µM 
in EL. When measured by ELISA, plasma adiponectin fell from 51 to 36 µg/mL between 
day -29 of LP and day 8 of EL (P < 0.05). Moreover, both assays gave similar relative 
reductions in plasma adiponectin between LP and EL (Figure 3.1A). The ELISA assay 
was adopted for all subsequent analysis.  
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A B
Figure)3.1)Comparison)of)adiponectin)assays)and)effect)of)increased)plasma)leptin)in)early)lactation)on)
plasma)adiponectin."Multiparous"dairy"cows"were"studied"on"day"329"± 2"(relative"to"parturition"on"day"0,"LP)"and"
again"on"day"+8"of"early"lactation"(EL).""(A) Plasma"samples"were"collected"at"2"h"intervals"over"a"6"h"sampling"window"
at"both"times"and"analyzed"for"adiponectin"by"western"immunoblotting"(Western)"or"by"a"bovine"adiponectin"ELISA"
(ELISA)."The"percent"reduction"in"plasma"adiponectin"between"LP"and"EL"is"shown."Each"bar"represents"the"mean"±
SE"of"10"cows."(B) Upon"completion"of"the"sampling"period"on"day"+"8"of"EL,"dairy"cows"were"randomly"assigned"to"a"
constant"intravenous"infusion"of"saline"(Control)"or"human"Leptin"(hLeptin)"for"96"consecutive"hours."Plasma"samples"
were"collected"between"88"and"94"h"of"infusion"and"analyzed"for"adiponectin"concentration"with"a"bovine"adiponectin"
ELISA."Each"bar"represents"the"mean"± SE"of"5"cows"per"treatment."
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Effect of energy balance immediately after parturition 
Next, we asked whether eliminating the energy deficit of EL impacted plasma 
adiponectin by comparing cows milked thrice daily or never milked. Energy balance and 
the change in body condition score over the four weeks of the study were -16.8 Mcal 
NEL/d and -0.6 units for lactating cows, and +12.1 Mcal NEL/d and 0.1 unit for non-
lactating cows (P < 0.001 for both variables). Plasma adiponectin increased by an average 
of 24% in both groups between week 1 and 4 and was 21% higher across time in non-
lactating cows than lactating cows (Figure 3.2A; Treatment and Time, P < 0.05 or less). 
When assessed across treatments, no relation existed between the change in body 
condition over this period and the change in plasma adiponectin (Figure 3.2B). There 
were however, modest relations between adiponectin and plasma indicators of energy 
status, with adiponectin increasing with leptin or insulin, and decreasing with NEFA 
(Figure 3.2C and results not shown; P < 0.05 or less).  
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A B
C
Figure*3.2*Effect*of*energy*balance*after*parturition*on*plasma*adiponectin."(A) After"parturition,"multiparous"
dairy"cows"were"milked"thrice"daily"(Lactating)"or"never"milked"(Non>lactating)."Plasma"samples"were"collected"
between"day"+5"and"+11"(Week"1)"and"again"between"day"+26"and"+33"(Week"4)"and"analyzed"for"adiponectin"
concentration"with"a"bovine"adiponectin"ELISA"(ELISA)."Each"bar"represents"the"mean"± SE"of"7"cows"per"treatment."
The"significant"effects"of"treatment"and"time"are"reported."(B) Relationship"between"the"change"in"plasma"adiponectin"
(! Plasma"adiponectin)"and"the"change"in"body"condition"(! Body"condition)"between"week"4"and"week"1"of"the"study."
(C) Relationships"between"plasma"adiponectin"and"plasma"leptin"or"non>esterified"fatty"acids"(NEFA)"over"the"first"4"
weeks"following"parturition.
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Reversal of the insulin and leptin deficits of early lactation 
The plasma concentration of leptin and insulin falls over the last few days of 
pregnancy and reach a nadir after parturition 19,20. To determine whether a fall in plasma 
leptin contributes to reduced adiponectin, cows received continuous IV infusions of 
saline or hLeptin between day 8 and 12 of lactation. After correcting for the bioactivity of 
hLeptin, the total effective leptin concentration was calculated within range of 
concentrations found in LP dairy cows 19. Relative to saline infusion, the hLeptin infusion 
caused a 3.5-fold increase in the effective plasma leptin concentration (2.3 vs. 8 ng/mL, P 
< 0.001) and a 45% increase in plasma T3 (0.91 vs. 1.32 ng/mL, P < 0.01), but did not 
affect energy variables such as feed intake and milk energy output 25. Plasma adiponectin 
remained unaffected after over 88 h of hLeptin treatment (Figure 3.1B).  
Next, we asked whether insulin had an effect on plasma adiponectin in either LP 
or EL. Dairy cows underwent hyperinsulinemic-euglycemic clamps for 96 h in LP and 
for 48 h in EL. Plasma insulin increased within 4 h from 1.8 to 4.0 ng/mL in LP and from 
0.7 to 2.5 ng/mL in EL, whereas the plasma glucose concentration remained within 10% 
of basal concentration at all times. Plasma adiponectin fell between LP and EL (Figure 
3.3; Stage, P < 0.001), but failed to increase with 48 h of hyperinsulinemia in either LP or 
EL. Prolonging the period of hyperinsulinemia to 96 h during LP was also without effects 
on plasma adiponectin (Basal vs. 96 h; 54 vs. 56 ng/mL). 
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Figure'3.3'Effect'of'euglycemic2hyperinsulinemia'in'late'pregnancy'and'early'lactation'on'plasma'adiponectin.'
Multiparous+dairy+cows+during+late+pregnancy+(LP,+day+731+± 1.5,+relative+to+parturition+on+day+0)+and+early+lactation+(EL,+
day++7+± 1.6)+were+studied+for+66+h+under+basal+condition+(Basal)+and+for+48+h+during+euglycemic7hyperinsulinemia+
(Insulin).+Plasma+samples+collected+during+the+basal+period+and+between+36+and+48+h+of+euglycemic7hyperinsulinemia+
were+analyzed+for+adiponectin+concentration+with+a+bovine+adiponectin+ELISA+(ELISA).+Each+bar+represents+the+mean+±
SE+of+6+cows.+The+significant+effect+of+physiological+stage+(Stage)+is+reported.+
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Exaggerating the GH increase or mimicking the NEFA increase of early lactation 
Plasma GH and NEFA increase in periparturient dairy cows 19,20. To assess the 
possible regulatory influence of GH on plasma adiponectin, LP or EL cows were treated 
with recombinant bST for 5 consecutive days. Plasma IGF-I was lower in EL than LP 
cows under basal condition (Figure 3.4A, Stage, P < 0.001). After 5 days of treatment, 
plasma IGF-I was increased by GH treatment, but to a lesser extend in EL than LP 
(Figure 3.4A; Stage ´ GH, P < 0.05). Adipose tissue, on the other hand, remained fully 
responsive to GH as shown by near identical GH-dependent Stat5 phosphorylation across 
physiological states (Figure 3.4B). Plasma adiponectin was again reduced in EL relative 
to LP (Stage, P < 0.05), but unaffected by GH in either LP or EL (Figure 3.4C). 
 Finally, the possibility that plasma NEFA represses plasma adiponectin was 
evaluated by IV infusion of a lipid emulsion in the absence or presence of glucagon for 
16 consecutive hours. Intralipid caused a 6-fold increase in plasma NEFA within 3 h of 
infusion (Saline vs. Intralipid, 102 vs. 576 µM; P < 0.001) and this increase persisted for 
the remainder of the infusion; glucagon had no additional effect on plasma NEFA 
(Intralipid + Glucagon, 613 µM). Plasma adiponectin remained unaffected throughout 
intralipid infusion irrespective of the presence or absence of glucagon (Figure 3.5).  
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to"5,"cows"received"daily"injections"of"GH"(40"mg"rbST/day)."(A) Plasma"samples"collected"during"the"basal"period"
(Basal)"and"on"day"5"of"GH"treatment"(GH)"were"analyzed"for"plasma"insulin*like"growth"factor"* I"(IGF*I)."Each"bar"
represents"the"mean"± SE"of"7"cows"per"treatment"and"stage."The"significant"effects"of"physiological"stage"(Stage),"GH"
treatment,"and"their"interaction"are"reported."(B)*Left: Adipose"tissue"was"obtained"on"day"1"of"the"study"period"
immediately"before"(*)"and"15"minutes"after"an"intrajugular"bolus"of"rbST"(GH)"(+)."Total"cellular"extracts"were"prepared"
from"tissues"and"analyzed"for"tyrosine"phosphorylated"Stat5"(pStat5)"and"total"Stat5"(Stat5)"by"western"immunoblotting."
A"representative"sample"is"shown"for"each"stage"and"treatment."Right:"The"pStat5"signal"was"normalized"to"total"Stat5"
signal"and"expressed"relative"to"LP"level"with"each"bar"representing"the"mean"± SE"of"7"cows."(C) Plasma"samples"
collected"during"the"basal"period"(Basal)"and"on"day"5"of"GH"treatment"(GH)"were"analyzed"for"adiponectin"
concentration"with"a"bovine"adiponectin"ELISA"(ELISA)."Each"bar"represents"the"mean"± SE"of"7"cows"per"stage."The"
significant"effect"of"physiological"stage"(Stage)"is"reported.""
LP EL
0.0
0.2
0.4
0.6
0.8
1.0
1.2
G
H
-a
ct
iv
at
ed
 S
ta
t5
 
ph
os
ph
or
yl
at
io
n 
(a
rb
itr
ar
y 
un
its
)
LP EL
0
20
40
60
80
100
Pl
as
m
a 
ad
ip
on
ec
tin
(µ
g/
m
L)
Basal
GH
Stage, P<0.001
LP EL
0
40
80
120
160
Pl
as
m
a 
IG
F-
I (
ng
/m
L) Basal
GH
Stage, P<0.001
GH, P<0.001
Stage × GH, P<0.05
	   69	  
 
 
Figure'3.5'Effect'of'increased'NEFA'on'plasma'adiponectin."Non&pregnant,"non&lactating"dairy"cows"were"treated"
over"16"h"with"combinations"of"intravenous"(IV)"infusion"of"saline"or"intralipid"20%"and"subcutaneous"(SC)"injections"of"
saline"or"glucagon."Treatments"were"IV"infusion"and"SC"injections"of"saline"(Control),"IV"infusion"of"intralipid"and"SC"
injections"of"saline"(intralipid),"or"IV"infusion"of"intralipid"and"SC"injection"of"glucagon"(intralipid"+"glucagon)."Plasma"
samples"were"collected"over"the"16"h"periods"and"analyzed"for"adiponectin"concentration"with"a"bovine"adiponectin"
ELISA"(ELISA)."Each"point"represents"the"mean"± SE"of"6"cows."
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DISCUSSION 
IR is a mechanism used by the modern dairy cow to promote glucose partitioning 
to the mammary gland at the expense of insulin sensitive tissues such as skeletal muscle 
or adipose tissue 33,34. Mechanisms regulating IR during EL in transition dairy cows are 
not well understood. In this context, we and others have shown that plasma adiponectin 
dropped in parallel with increased IR in periparturient dairy cows 17,18,35. Adiponectin is 
an insulin sensitizing hormone and therefore its reduction could contribute to the IR of 
periparturient dairy cows. Virtually no information is available on mechanisms regulating 
plasma adiponectin in periparturient dairy cattle, prompting us to examine possible 
regulatory effects of metabolic and hormonal factors changing in a dynamic manner 
during this period. 
The profile of plasma adiponectin in periparturient dairy cows consists of two 
reciprocal patterns; a falling phase over the last 2 – 3 weeks of pregnancy followed by a 
rising phase after parturition 17,35. The placenta has been suggested to produce 
adiponectin in rats and humans 36. Hence, an obvious question is whether the placenta 
could account for the falling phase through reduced adiponectin production in LP and its 
expulsion at parturition. More recent studies performed on mid and late gestation human 
placenta, primary human cytotrophoblasts, and placental choriocarcinoma cell lines (Jeg-
3, JAR, and BeWo) have ruled out placental production 36–40. Moreover, adiponectin 
expression was less than 0.5% of maternal adipose tissue expression at both day 50 and 
135 of gestation in the sheep (Boisclair et al unpublished data). Given the close 
evolutionary relation between sheep and cattle, it is unlikely that the bovine placenta is a 
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source of adiponectin and a contributing factor to its falling plasma concentration in late 
pregnant dairy cows. 
In rodents and humans, loss of adiposity and NEB increase plasma adiponectin. 
The relation between energy balance and adiposity and plasma adiponectin has been 
investigated in non-lactating, non-pregnant dairy cows and in cows from the last month 
of gestation through the first 12 weeks of lactation 35,41. The contribution of these factors 
to changes in plasma adiponectin around parturition remains unclear. Accordingly, we 
used dairy cows dried off immediately after parturition to test the possibility that these 
factors contribute to the recovery of plasma adiponectin after parturition. In particular, 
the non-lactating dairy cows completely avoided energy insufficiency after parturition 
and did not experience a loss of adiposity over the next 4 weeks. Against expectations, 
non-lactating dairy cows not only maintained higher plasma adiponectin than lactating 
dairy cows, but also recovered plasma adiponectin at similar rates as lactating dairy cows. 
Measurable amounts of adiponectin are secreted in milk 35, raising the possibility that the 
higher plasma adiponectin of non-lactating dairy cows relates to absence of adiponectin 
excretion in milk. The fraction of the steady state plasma adiponectin pool appearing 
daily in milk is 5% or less 35. Adiponectin has a relatively short half-life (i.e. 90 min) 42, 
implying that this fraction would be even less if calculated on the basis of daily 
adiponectin production. Therefore milk adiponectin secretion 35 cannot account for the 
21% difference in plasma adiponectin between lactating and non-lactating dairy cows. 
Finally, the positive effect of energy balance in EL on plasma adiponectin is in contrast to 
the lack of any response when dairy cows experience severe energy insufficiency in mid-
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lactation 35. Overall, our data suggest that the reduction in plasma adiponectin after 
parturition is driven in part by NEB and that adiponectin recovery after parturition occurs 
independently of loss of adiposity. 
The periparturient period is characterized by rapid reductions in plasma leptin and 
insulin, raising the possibility that either one or both of these hormones are positive 
regulators of adiponectin production. In apparent support for this model, plasma 
adiponectin increases after leptin therapy of leptin-deficient humans and mice 21,43. 
However, we failed to detect increased plasma adiponectin in EL dairy cows, despite a 
3.5-fold increase in plasma leptin. It is also important to mention that the positive effect 
of leptin therapy seen in leptin-deficient humans and mice is likely a consequence of 
substantial loss of adiposity rather than a direct leptin effect. In similar fashion to the lack 
of leptin effects, increasing plasma insulin in either LP or EL was also without any 
effects on plasma adiponectin. This result is not only inconsistent with a positive role for 
insulin in the cow, but also discordant with results in humans and rodents showing that 
loss of function mutations of the insulin receptor increase plasma adiponectin, whereas 
euglycemic-hyperinsulinemic clamps uniformly reduce plasma adiponectin 23,44–46. 
Interestingly, effects of insulin in humans are not seen on HMW adiponectin 23. 
Accordingly, it is possible that the lack of insulin effect in dairy cows relate to circulation 
of adiponectin predominantly in the HMW form 17. Finally, the periparturient period in 
dairy cows is associated with a reduction in the plasma concentration of thyroid 
hormones 25,47. Hypothyroidism in human patients is associated with reduced plasma 
adiponectin, whereas hyperthyroidism in both humans and rodents has the opposite 
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effects 48,49. The hypothyroid state of EL is also unlikely to account for reduced 
adiponectin, because it was partially corrected by leptin in the leptin infusion experiment 
25. A similar conclusion applies to the IGF-I deficit of EL, which was also completely 
reversed after 48 h of euglycemic-hyperinsulinemia in EL 20.  
Plasma GH and NEFA have been implicated as drivers of IR and both are 
increased in EL dairy cows 20,34. In the case of both mice and humans, existing data 
suggest the possibility that adiponectin mediates the effect of GH on IR. Thus, GH 
receptor knockout mice have elevated plasma adiponectin and insulin sensitivity, despite 
increased fatness 50,51. Similarly, increased insulin sensitivity and plasma adiponectin 
coexist in Laron dwarf patients, but both are reduced in acromegaly patients 52,53. 
Therefore, we tested the possibility that GH inhibits adiponectin production by treating 
LP and EL dairy cows with exogenous GH. As previously shown 19,20, plasma IGF-I was 
lower in EL than LP and GH increased plasma IGF-I to a larger extent in LP than EL . 
The attenuated increase in plasma IGF-I reflects reduced hepatic GH responsiveness as a 
result of loss of GH receptor expression in EL 54. On the other hand, adipose tissue 
remains GH-responsive in both LP and EL as demonstrated by equally robust GH-
dependent Stat5 activation across physiological states. Despite this, GH treatment for 5 
consecutive days had no impact on plasma adiponectin irrespective of physiological state.  
Plasma NEFA also contributes to IR 55,56, particularly when their levels are 
excessively elevated in EL as a consequence of over nutrition and/or obesity in LP 57,58. 
Plasma NEFA promotes IR by promoting synthesis of lipid intermediates (i.e. ceramide 
species, diacylglycerol, etc.) and by activating the production of pro-inflammatory 
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cytokines such as tumor necrosis factor a (TNFa) 59–61. Interestingly, intralipid, 
ceramide, and TNFa have been shown to repress adiponectin production both in vivo and 
in vitro 62–64. Despite these data implicating NEFA as a repressor of adiponectin 
production, a 6-fold increase in plasma NEFA had no effect on plasma adiponectin. 
In summary, we show that changes in energy balance during the onset of lactation 
mediate plasma adiponectin. Rapid and sudden changes in plasma levels of leptin insulin, 
GH, and NEFA occur in parallel to this effect, and were shown to regulate plasma 
adiponectin in rodents or humans 21–23. However, our results suggest that these factors 
have no effect on plasma adiponectin in periparturient dairy cows. Future work in dairy 
cows could aim to explore what regulates the variation in plasma adiponectin in the 
periparturient period. 
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CHAPTER 4 
 
IDENTIFYING FACTORS REGULATING ADIPONECTIN SECRETION IN 
PRIMARY BOVINE ADIPOCYTES2  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
___________________________ 
 
2Krumm C.S., Giesy S.L., Orndorff C.L., and Boisclair Y.R. (2016) Identifying factors 
regulating adiponectin secretion in primary bovine adipocytes. In preparation. 
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INTRODUCTION 
Early lactating (EL) dairy cows suffer from major deficits in virtually all major 
class of organic nutrients, including the lactose precursor glucose 1. Dairy cows cope with 
this nutritional insufficiency by calling on adaptations such as insulin resistance (IR). IR 
creates a metabolic environment promoting lactose synthesis, because mammary glucose 
uptake occurs in an insulin-independent manner 2. Mechanisms leading to IR in 
periparturient dairy cows are not completely understood. Increased growth hormone 
(GH) secretion in EL likely plays a role given its ability to suppress insulin-stimulated 
glucose uptake in adipose tissue and skeletal muscle 2–4. The increased circulating non-
esterified fatty acid (NEFA) of EL may also be involved through induction of signals 
interfering with insulin signaling such as ceramide and the cytokine tumor necrosis factor 
a (TNFa) 5–9. One hormone that has not been extensively studied in the context of IR of 
EL is adiponectin. We and others have shown that the plasma concentration of 
adiponectin drops in parallel with the rise of IR in transition dairy cows 10–12. This 
observation may be relevant to the IR of EL because work in other species have 
implicated adiponectin as an insulin-sensitizing hormone 13–15.  
Adiponectin is a 30-kDa protein secreted exclusively by white adipose tissue 
(WAT) 16–18. Unlike most other adipokines, adiponectin circulates as low molecular 
weight (LMW), medium molecular weight (MMW), and high molecular weight (HMW) 
complexes containing 3, 6, or 18 or more adiponectin monomers 19,20. Adiponectin 
oligomer assembly occurs within the endoplasmic reticulum (ER) and involves a subset 
of ER chaperone proteins [i.e. glucose-regulated protein, 78 kDa (Grp78), endoplasmic 
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reticulum protein 44 (Erp44), endoplasmic reticulum oxidoreductase α (ERO1-La), 
protein disulfide isomerase associated 6 (Pdia6), disulfide bond A oxidoreductase-like 
protein (DsbA-L), and gamma adaptin ear containing, ARF binding protein 1 (Gga1)] 
21,22. Interestingly, the periparturient reduction in plasma adiponectin in dairy cows 
occurred in the absence of any changes in adiponectin mRNA, but was associated with 
reduced expression of Grp78, Erp44, and Pdia6 in WAT 10. These chaperones are 
regulated in part through the master regulator of ER homeostasis x-box binding protein 1 
(Xbp1) 23,24.  
These data led us to hypothesize that Xbp1 expression is reduced in WAT in EL, 
leading to reduced ER chaperone expression and adiponectin secretion. Accordingly, we 
first determined whether Xbp1 is regulated in adipose tissue during the transition from 
late pregnancy (LP) to EL. Second, we asked whether Xbp1 overexpression in adipocytes 
increases ER chaperone expression and adiponectin secretion. Finally, we examined the 
possibility that effects of other factors on adiponectin secretion are explained in part by 
regulation of ER chaperones.  
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MATERIALS & METHODS 
Source of adipose tissue 
All experiments were performed on multiparous Holstein cows and were 
approved by the Cornell Institutional Animal Care and Use Committee. A previously 
described cow study was used to measure changes in Xbp1 gene expression in WAT 
during the transition period 25. WAT was obtained from the tail head subcutaneous depot 
of ten cows in LP (day -29 ± 2, relative to parturition on day 0) and again in EL (day +8). 
WAT samples were frozen at -80°C until used for total RNA isolation. 
WAT used for isolation of bovine stromovascular (SVC) cells were obtained from 
dairy cows at the start of the dry off period approximately 7 weeks before expected 
parturition. All cows were of parity ³ 1 and were in good body condition (body condition 
score ³ 3.0). Immediately after biopsy, WAT was immersed in growth media 
[DMEM/F12 (1:1 vol; Thermo Fisher; Waltham, MA) supplemented with 10% fetalgro 
(Rocky Mountain Biologicals, Inc.; Missoula, MT), penicillin-streptomycin (50 U/mL; 
Thermo Fisher; Waltham, MA), GlutaMAX (2 mM; Thermo Fisher; Waltham, MA), and 
amphotericin B (1 µg/mL; Thermo Fisher; Waltham, MA)] and transported to the 
laboratory. 
 
Isolation, differentiation, and study of bovine stromovascular cells (SVC) 
Bovine SVCs were isolated and differentiated into adipocytes as previously 
described 26. In brief, WAT was rinsed in a solution of 20% betadine and growth media, 
followed by a single wash with fresh growth media. Pieces of WAT (~ 1 mm3) were 
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placed onto 100 mm dishes and kept in place with a coverslip attached to the growth 
surface of the cell dish with vacuum grease. After 10 days, bovine SVCs growing out of 
the explants were recovered by trypsinization and seeded into 100 mm dishes. They were 
reseeded when 90% confluent into 60 mm dishes pre-coated with gelatin (Sigma Aldrich; 
St. Louis, MI). SVC were incubated over the first 48 h with adipocyte differentiation 
media [DMEM/F12 (1:1 vol) + insulin (10 µg/mL; Sigma Aldrich; St. Louis, MI), 
rosiglitazone (1 µM; Sigma Aldrich; St. Louis, MI), intralipid (2%; Sigma Aldrich; St. 
Louis, MI), penicillin-streptomycin (50 U/mL; Thermo Fisher; Waltham, MA), 
GlutaMAX (2 mM; Thermo Fisher; Waltham, MA), and amphotericin B (1 µg/mL; 
Thermo Fisher; Waltham, MA)] supplemented with dexamethasone (0.25 µM; Sigma 
Aldrich; St. Louis, MI) and 3-isobutyl-1-methylxanthine (IBMX; 0.5 mM; Sigma 
Aldrich; St. Louis, MI), and adipocyte differentiation media alone thereafter. WAT 
explants and SVC were kept at 37°C and 5% CO2 at all times, with media changed every 
2 days. 
For experiments involving adenoviruses, SVC were infected at 1700 h on day 6 of 
differentiation followed by media change 15 h later. Media and total RNA were collected 
as indicated in figure legends. In other studies, differentiated SVC were incubated 
between day 6 and 8 with either PBS (Control), 100 ng/mL bovine GH (Protiva; St. 
Louis, MI), or 10 ng/mL of human TNFa (R&D systems; Minneapolis, MN). Media and 
total RNA were collected on day 8 of differentiation. Oil-red O staining was used to 
confirm lipid accumulation in differentiated SVC. In brief, cells were washed with PBS 
and fixed with 10% formalin for 1 hour at room temperature. Following two washes with 
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60% isopropanol, bovine adipocytes were stained with Oil-red O (Sigma Aldrich; St. 
Louis, MO) for 10 min at room temperature and analyzed by Axiovert 40 Microscope 
bright light microscopy (Carl Zeiss; Oberkochen, Germany) at 10X magnification. 
 
Construction of an adenovirus expressing bovine Xbp1S 
Bovine spliced variant (Xbp1S) cDNA was generated by reverse transcription of total 
mRNA from bovine WAT followed by high fidelity amplification using previously 
described procedures 27. Primers used to amplify bovine Xbp1S were 5’-­‐‑
CTGGTACCCGCCACCATGGTGGT GGTTGCACCC-3’ and 5’-
AAGCGGCCGCTTAGACACTAATCAGCTGG-3’. The resulting cDNA was subcloned 
into the adenoviral shuttle vector pAd-CMV and shown by sequencing to correspond 
exactly to bovine Xbp1S (Ref Seq NM_001034727.3). The bovine Xbp1S adenovirus was 
generated using the AdEasy system as previously described 28. In brief, the plasmid was 
linearized using the restriction enzyme PmeI and transformed into AdEasier bacteria 
containing the adenoviral backbone plasmid pAdEasy-1. As a result, the bovine Xbp1S 
cDNA was recombined into the pAdEasy-1, giving pAdEasy-Xbp1S. Adenovirus 
particles were generated by transfecting human embryonic kidney 293a (HEK293a) cells 
with Pac-I-linearized pAdEasy-Xbp1S using Lipofectamine 2000 (Thermo Fisher; 
Waltham, MA). The virus was then amplified via 5 rounds of HEK293a infection. 
Adenoviruses expressing mCherry (Cherry) under the control of the CMV promoter 
(Cherry; Vector Biolabs; Malvern, PA) were amplified in parallel using the exact same 
procedure.	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Western blot analysis 
Media were pooled from four individual 60 mm dishes and concentrated to 100 
µL using centrifugal units with a molecular weight cutoff of 10 kDa (Amicon ultra-4; 
Merck; Darmstadt, Germany). Total cellular extracts were prepared from bovine 
adipocytes by lysis with radioimmunoprecipitation assay buffer [10 mM tris-HCl (pH 
7.4), 150 mM NaCl, 1% nonidet P-40, 1 mM phenylmethylsulfonyl fluoride, 1 mM 
EDTA, 1 mM NaF, 0.25% sodium deoxycholate, and 10% glycerol, supplemented with 
protease and phosphatase inhibitors (Halt TM phosphatase inhibitor mixture EDTA-free; 
Thermo Fisher; Waltham, MA)]. Protein concentrations of cellular extracts were 
determined with the BCA assay (Thermo Fisher; Waltham, MA).  Concentrated media 
(18 µL) or fixed amounts of cellular extract (20 – 40 µg) were separated on 13 % 
polyacrylamide gels and transferred onto nitrocellulose membranes (Protran, Schleicher, 
and Schuell Bioscience; Dassel, Germany). Membranes were blocked in 5% non-fat dried 
skim milk with tween-20 (0.05 M Tris-HCl (pH 7.4), 0.2 M NaCl and 0.1% Tween-20). 
Membranes were then immunodecorated with a mouse primary antibody against human 
adiponectin (A gift from Dr. Tohru Funahashi, Osaka University; Suita, Japan) and a 
rabbit primary antibody against human β-actin (Cell Signaling; Danvers, MA). Primary 
antibodies were diluted at 1:1,000 (β-actin) or 1:20,000 (adiponectin) in blocking 
solution. Signals were developed with 1:20,000 dilution of either IR Dye 800 goat anti-
rabbit or goat anti-mouse secondary antibody (LI-COR Biotechnology, Lincoln, NE) and 
visualized with the LI-COR Odyssey infrared imaging system. 
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RNA extraction and analysis of gene expression 
WAT biopsies and bovine adipocytes were lysed with Qiazol (Qiagen; Hilden, 
Germany) followed by total RNA purification using RNeasy Mini columns and on-
column RNase-free DNase treatment (Qiagen; Hilden, Germany). Reverse transcription 
reactions were performed with 1 µg of mRNA in a total 20 µL volume with the high-
capacity cDNA reverse transcription kit and RNase inhibitor (Applied Biosystems; Foster 
City, CA). Gene expression was analyzed with quantitative real-time PCR assays using 
Power SYBR Green Mix (Applied Biosystems; Foster City, CA). Real-time PCR assays 
were performed in duplicate with a total 25 µL reaction volume containing 500 nM 
concentration of each primer and reverse transcribed mRNA (25 ng except 2.5 ng for the 
internal standard gene 18S). The sequences of all primers used are given in Appendix I. 
mRNA data were analyzed using a relative standard curve based on serial dilution of 
pooled cDNA from bovine adipocytes. Unknown sample expression levels were 
calculated from the standard curve and adjusted to the geometric mean expression of b-
Actin and 18S.  
 
Statistical analysis 
Data were analyzed by a mixed model using the fit model procedure of JMP Pro 
11.0 statistical software (SAS Institute, Cary, NC). For Xbp1S mRNA abundance during 
the transition period, the model accounted for physiological stage (LP vs. EL) as the fixed 
effect and animal as the random effect. For the time course of differentiation, the model 
accounted for time (0, 4, 6, 8, and 10 days) as the fixed effect and cell dish as the random 
effect. If significant, the effect of time was partitioned into linear, quadratic, and cubic 
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contrasts. For the effect of Xbp1S overexpression, the model accounted for adenovirus 
(Cherry vs. Xbp1S) as the fixed effect and cell dish as the random effect. For the intralipid 
experiment, the model accounted for treatment (- vs. + intralipid) as the fixed effect and 
cell dish as the random effect. For the TNFa and GH experiments, the model accounted 
for treatment (either Control vs. TNFa or GH) as the fixed effect and cell dish as the 
random effect. The level of statistical significance was set at P < 0.05. 
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RESULTS 
Reduced Xbp1 expression in adipose tissue of transition dairy cows 
In previous work, we showed that plasma adiponectin dropped by 40% between 
LP and EL 10. This reduction occurred in absence of changes in adiponectin mRNA in 
adipose tissue, but was associated with attenuated expression of the Xbp1-dependent ER 
chaperones Grp78, Erp44, and Pdia6 10. Accordingly, we asked whether Xbp1 expression 
is regulated in WAT of transition dairy cows. WAT expression of both total Xbp1 
(Xbp1T) and its active spliced variant Xbp1 (Xbp1S) was reduced by 42 and 50% 
respectively between LP and EL (Figure 4.1; P < 0.001). These data raise the possibility 
that lower expression of Xbp1 expression in EL contributes to reduced plasma 
adiponectin. 
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Figure'4.1'Effect'of'the'transition'period'on'Xbp1'expression'in'adipose'tissue."Adipose"tissue"was"collected"from"
multiparous"cows"on"day"529"± 2"(relative"to"parturition"on"day"0,"LP)"and"again"on"day"+8"of"lactation"(EL)."(A) Total"
mRNA"was"isolated"and"analyzed"by"quantitative"real5time"PCR"for"expression"of"total"x5box"binding"protein"1"(Xbp1T)"
and"spliced"variant"Xbp1"(Xbp1S)."The"expression"of"each"gene"is"relative"to"LP."Each"bar"represents"the"mean"± SE"of"
mRNA"abundance"for"the"indicated"gene"(n"="10)."***,"P"<"0.001.
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Capacity of primary bovine adipocytes to secrete adiponectin 
 As a first step to determine whether Xbp1S can regulate adiponectin production, 
we asked whether SVC differentiated into adiponectin-secreting adipocytes. Bovine SVC 
were grown out of WAT explants and upon confluence, incubated in differentiation 
media over 10 days. Lipid accumulation was not detected by Oil-red O on day 0, but 
became obvious by day 6 of differentiation and peaked in abundance and intensity by day 
8 (Figure 4.2A). Acquisition of the adipogenic phenotype was confirmed by maximal 
expression of the adipogenic marker fatty acid binding protein-4 (Fabp4) within 4 days of 
incubation in differentiation media (Figure 4.2B; P < 0.01). Leptin and adiponectin 
mRNA were undetectable on differentiation day 0, but increased in a linear fashion over 
the next 10 days (Figure 4.2B; P < 0.05 or less). Finally, we asked whether adiponectin 
was produced by assessing its presence in cells and media collected during differentiation 
(Figure 4.2C). Adiponectin was undetectable at all times in cellular extracts and in media 
collected between days 0 and 4 of differentiation. Adiponectin was first seen in media 
collected between day 4 and 6 of differentiation and kept increasing in abundance over 
the next 2 collection periods (Figure 4.2C). Together, these findings demonstrate that 
bovine SVC differentiated into adipocytes produce and secrete adiponectin.  
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Effect of Xbp1 overexpression on ER chaperones and adiponectin secretion 
 First, we asked whether adenoviruses could efficiently infect cells undergoing 
adipogenic differentiation. Bovine cells were infected with adenoviruses expressing 
Cherry on day 6 of differentiation, followed by determination of fluorescence 96 h later. 
As shown in Figure 4.3A, fluorescence was detected in virtually all cells, and was 
particularly strong in lipid-accumulating cells. 
 Next, cells were infected on day 6 of differentiation with adenoviruses expressing 
either Cherry or Xbp1S and analyzed 72 h later. Infection with Xbp1S adenovirus caused 
a 1.5 to 5-fold increase in the expression of the ER chaperones Grp78, Erp44, and Pdia6. 
(Figure 4.3B; P < 0.05 or less). Xbp1S overexpression did not alter adiponectin 
expression (Figure 4.3C). 
 Finally, effect of Xbp1S overexpression was assessed by measuring adiponectin 
secreted in media. As shown in Figure 4.3D, Xbp1S overexpression did not impact the 
amount of adiponectin secreted in media between 48 and 72 h following infection. 
Similarly, prolonging the period of infection and doubling the adenovirus dose did not 
affect adiponectin secretion in media between 72 and 96 h following infection. Overall, 
these data show that Xbp1S is a positive regulator of Grp78, Erp44, and Pdia6 expression, 
but do not support a role for Xbp1S in regulating adiponectin production in bovine 
adipocytes. 
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Effect of intralipid on ER chaperone expression and adiponectin secretion 
Conditions used for converting SVC to adipocytes are very similar across species, 
except for the presence of exogenous lipid when using bovine SVC 26,29–31. Accordingly, 
we asked whether intralipid supplementation was necessary for adiponectin secretion by 
differentiated SVC. SVCs were cultured for 8 days in differentiation media supplemented 
with or without intralipid. The presence of intralipid increased the density and intensity of 
lipid-containing cells, but had no effect on mRNA abundance of the adipocyte 
differentiation marker Fabp4 (Figure 4.4A). Surprisingly, absence of intralipid abrogated 
adiponectin secretion in media, even though adiponectin mRNA was unaffected by the 
presence or absence of intralipid (Figure 4.4B). Accordingly, we asked whether absence 
of adiponectin secretion was associated with reduced expression of ER chaperones and 
their transcriptional regulators Xbp1 and ATF6. As shown in Figure 4.4C, absence of 
intralipid had no effect on the mRNA abundance of ER-chaperones (Grp78, Erp44, 
ERO1-La, Pdia6, DsbA-L, and Gga1), Xbp1S or ATF6a . These data show that intralipid 
is required for adiponectin production by a mechanism that does not involve Xbp1S, 
ATF6a, and ER chaperones. 
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Effect of TNFa and GH on ER chaperone expression and adiponectin secretion 
 TNFa and GH suppress adiponectin secretion in 3T3-L1 adipocytes and human 
adipose tissue explants respectively 32,33. To determine whether similar effects are seen in 
differentiated bovine SVC, cells were treated with TNFa or GH between day 6 and 8 of 
differentiation. TNFa treatment did not alter lipid accumulation in cells differentiated for 
8 days, but caused a 27% reduction in the mRNA abundance of the adipocyte 
differentiation marker Fabp4 (Figure 4.5A; P < 0.05). Treatment with TNFa decreased 
adiponectin mRNA abundance by 86% (Figure 4.5B; P < 0.05) and adiponectin in media 
by 29% (Figure 4.5C; P < 0.01). TNFa also reduced expression of Grp78 by 44%, but 
otherwise had no effect on the expression of other ER chaperones or the expression of 
Xbp1S or ATF6a (Figure 4.5D). On the other hand, GH treatment had no effect on 
indices of differentiation (Oil-red O staining and Fabp4 expression) or adiponectin 
production (mRNA level and adiponectin secretion in media) [Figures 4.6B – D]. These 
data suggest that effects of TNFa on adiponectin secretion are mediated predominantly 
through reduced adiponectin mRNA rather than repression of ER chaperone expression. 
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DISCUSSION 
 The plasma adiponectin concentration in transition dairy cows drops by 40% 
during the last 2 – 3 weeks before parturition, and is followed by a gradual rise during 
lactation 10–12. Periparturient changes in plasma adiponectin, however, occur in absence 
of changes in adiponectin mRNA expression 10,34.  This is best illustrated by a recent 
study where changes in plasma adiponectin and indices of adiponectin production in fat 
depots were studied between parturition and day 105 of lactation. This work showed that 
adiponectin recovered fully in both plasma and individual depots by day 42 of lactation in 
complete absence of any changes in mRNA 35,36. A lack of relation between changes in 
adiponectin mRNA and plasma adiponectin is not unique to transition dairy cows. For 
example, human participants undergoing extensive weight loss experienced increased 
plasma adiponectin in absence of changes in adiponectin mRNA 37. Longitudinal studies 
following rhesus monkeys through the development of obesity and type 2 diabetes 
showed a drop in plasma adiponectin, independent of changes in adiponectin mRNA 38. 
Therefore, mechanisms other than changes in WAT adiponectin mRNA are involved in 
reducing the plasma concentration of adiponectin in many conditions including the 
transition dairy cow. In this context, there is evidence of a role by ER chaperone in 
controlling the assembly of adiponectin into oligomeric complexes 22,39–42. For example, 
ERO1-Lα overexpression increased adiponectin secretion in 3T3-L1 adipocytes 39. 
Overexpressing DsbA-L in 3T3-L1 adipocytes and adipose tissue in mice enhanced 
adiponectin secretion 41,43. Consistent with a reduced capacity of WAT to assemble 
adiponectin complexes after parturition, we previously showed that ER chaperone 
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proteins including Grp78, Erp44, and Pdia6 expression were lower in EL than LP in 
transition dairy cows 10. These and other chaperones (e.g. DsbA-L) are positively 
regulated by the master regulator of ER homeostasis Xbp1. Moreover, Xbp1S 
overexpression in mouse WAT led to increased ER chaperone expression and increased 
adiponectin production and secretion 44. Consistent with a role for Xbp1, we observed 
reduced Xbp1S expression during the transition from LP to EL. This prompted us to 
assess the possibility that Xbp1S regulates adiponectin production through effects on key 
ER chaperones.  
 We evaluated this possibility using SVC differentiated into adipocytes. Others 
had previously shown that this system faithfully recapitulated lipogenic regulation 26, but 
whether it was capable of producing and secreting adiponectin was unknown. 
Adiponectin mRNA was undetectable on day 0 of differentiation, but increased in a linear 
fashion over the next 10 days. Detection of adiponectin in media showed a similar 
increase over 10 days of differentiation. We next tested whether overexpressing Xbp1S 
could increase adiponectin production and secretion through increased ER chaperone 
expression. Accordingly, adipocytes were infected with adenovirus encoding bovine 
Xbp1S. Overexpressing Xbp1S increased the expression of ER chaperones Grp78, Erp44, 
and Pdia6 1.5 to 5-fold, but had no effect on adiponectin mRNA and more importantly on 
adiponectin secretion in media. It is possible that ER chaperone expression in bovine 
adipocytes is already sufficient for oligomer assembly and secretion of adiponectin, and 
that further increasing their expression has no effect. It will be important in future work 
to assess whether knockdown of Xbp1S or its dependent set of ER chaperones (Grp78, 
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Erp44, or Pdia6) affect adiponectin secretion. Finally, also involved is the transcription 
factor ATF6a in regulating ER homeostasis 24, and some ER chaperones such as Grp78 
are more dependent on ATF6a rather than Xbp1S 45. Moreover, transcriptional activation 
of several ER chaperone proteins require both Xbp1S and ATF6a 46. These data suggest 
that experiments knocking out Xbp1S, ATF6a, or both should be pursued in this system. 
Differentiation of SVC to adipocytes requires a conserved cocktail of reagents 
across all species 30,31. Ruminants differ somewhat in that this cocktail is usually 
supplemented by exogenous lipid such as intralipid 26,29.  This prompted us to ask 
whether exogenous lipid impacted adiponectin production and secretion, and whether 
variation in ER chaperones was involved in this effect. Differentiated adipocytes secreted 
adiponectin in media only in the presence of intralipid, even though adiponectin mRNA 
was unaffected. We next asked whether intralipid-mediated adiponectin secretion was 
associated with changes in ER chaperone expression. Intralipid had no effect on 
expression of ER chaperones (Grp78, Erp44, ERO1-La, DsbA-L, and Gga1). Intralipid 
had a similar lack of effect on expression of transcription factors mediating ER chaperone 
expression (Xbp1S and ATF6a). In direct agreement with our studies, treatment with 
fatty acids including palmitic acid, oleic acid, linoleic acid, eicosapentaenoic acid, or 
docosahexaenoic acid increased adiponectin secretion in absence of changes in the 
expression of ER chaperones in 3T3-L1 adipocytes 47.  
The periparturient period is characterized by rapid increases in drivers of IR 
including plasma GH and adipose TNFa, suggesting a model whereby either one or both 
of these hormones are negative regulators of adiponectin production and secretion 8,48. 
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We observed that TNFa suppressed adiponectin mRNA by 86% and adiponectin 
secretion in media by 29% in bovine adipocytes. The ability of TNFa to inhibit 
adiponectin mRNA abundance and secretion has also been demonstrated in 3T3-L1 
adipocytes and mice 49–51. Moreover, TNFa exerted this effect in part by antagonizing 
expression of the ER chaperone proteins Erp44 and DsbA-L 51. Accordingly, we asked 
whether inhibition of adiponectin secretion in media is exclusively due to inhibition of 
adiponectin transcription or in part due to changes in expression of ER chaperones. 
However, TNFa failed to inhibit expression of Erp44 and DsbA-L in bovine adipocytes. 
A similar lack of effect was found on expression of transcription factors mediating ER 
chaperone expression (Xbp1S and ATF6a). Therefore, it is likely that suppression of 
adiponectin mRNA transcription, rather than post-transcriptional modifications account 
for most of the TNFa-induced suppression of adiponectin secretion in bovine adipocytes. 
In contrast to TNFa-mediated suppression of adiponectin secretion, GH treatment failed 
to induce any effects on adiponectin mRNA or secretion in media in bovine adipocytes. 
This result is inconsistent with an inverse relation between GH and adiponectin in rodents 
and humans 52–55, but in agreement with the failure of chronic GH treatment to alter 
plasma adiponectin in transition dairy cows (Chapter 3).  
In summary, we determined that Xbp1S expression in adipose tissue drops from 
LP to EL in the transition dairy cow. Using a primary bovine adipocyte system, we 
showed that Xbp1S overexpression regulates expression of the ER chaperone proteins 
Grp78, Erp44, and Pdia6, but not adiponectin expression or secretion. Finally, we showed 
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that while TNFa suppressed adiponectin secretion, these effects were not due to 
regulation by ER chaperones. 
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CHAPTER 5 
 
DEFECTIVE LIPID METABOLISM IN LIVER-SPECIFIC SEL1L KNOCKOUT 
MICE FED AN ATHEROGENIC DIET3 
 
 
 
 
 
 
 
 
 
 
 
 
___________________________ 
 
3Krumm C.S., Francisco A.B.., Chang W.H.., Deng K.Y., Boisclair Y.R., and Long Q. 
(2016) Defective lipid metabolism in liver-specific sel1l knockout mice fed an 
atherogenic diet.  
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INTRODUCTION 
Protein misfolding and aggregation have been associated with an array of diseases 
including type 1 diabetes, chronic viral hepatitis, and nonalcoholic fatty liver 1,2. 
Endoplasmic reticulum (ER) stress resulting from protein misfolding or ER malfunction 
can activate one of several quality control systems. For example, activation of the 
unfolded protein response (UPR) can transcriptionally activate a subset of ER chaperones 
to increase the folding capacity of the ER 3. In addition, activation of the endoplasmic-
reticulum associated degradation (ERAD) system results in the retrotranslocation of 
unfolded or misfolded proteins across the ER membrane, followed by their degradation 
by the cytosolic proteasomal degradation system 3. Several reports have shown cell-
specific differences in UPR and ERAD responses to ER stress. Animal models are 
therefore required to further elucidate the tissue-specific functions of UPR and ERAD. 
Moreover, while many models of defective UPR have been developed, few models of 
ERAD deficiencies exist. 
In yeast, hydroxymethylglutaryl reductase degradation protein 3 (Hrd3p) is 
critical in maintaining stability and communication of different components of the ERAD 
system 4,5. Sel-1 suppressor of lin-12-like protein (Sel1l), the mammalian homolog of 
Hrd3p, is an integral ER resident glycoprotein and is also required for ERAD-mediated 
dislocation of misfolded proteins 4. Sel1l expression is highly induced by the activating 
transcription factor-6 α (ATF6α) branch of the UPR in response to ER stress 6. The 
essential role of Sel1l in mammals has recently been demonstrated using Sel1l knockout 
mice. For example, mice lacking Sel1l exhibited early lethality as well as increased 
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activation of UPR in the pancreas 7. Together, these studies highlight the conserved 
significance of Sel1l in sustaining ER homeostasis across species. 
The liver is involved in involved in plasma protein synthesis, cholesterol 
biosynthesis, and lipoprotein assembly and as a result, is highly enriched in ER 
organelles 1. ER stress and UPR activation are elevated in a myriad of liver diseases 
traced to defective lipid metabolism (i.e. steatosis, choleostasis, and alcohol-induced liver 
injury) 8,9. However, mechanisms connecting ER stress and lipid homeostasis are poorly 
understood. In this context, a recent study implicated Sel1l in the regulation of lipid 
metabolism in adipose tissue 10. Accordingly, the present study was designed to ask 
whether Sel1l regulates lipid metabolism in liver. 
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MATERIALS & METHODS 
Animals 
 All procedures were approved by the Cornell Institutional Animal Care and Use 
Committee. Sel1lf/f mice with loxP sites on either side of exon 6 in the Sel1l gene were 
generated as recently described and maintained on a C57BL/6 background 7. Albumin-
Cre mice were obtained from the Jackson Laboratory (Bar Harbor, ME) and maintained 
on a C57BL/6 background. Experimental animals were generated by intercrossing Sel1lf/f 
female mice with Sel1lf/f male mice carrying the albumin-Cre transgene. Offspring 
retained for studies were either Sel1lf/f (designated WT) or Sel1lf/f carrying the albumin-
Cre transgene (designated ΔSel1lLiver). Litters were weaned and genotyped at 3 weeks of 
age. All terminal procedures involved euthanasia by CO2 asphyxiation. 
Mice were routinely housed on a 12-h light/12-h dark cycle and fed a normal 
chow diet (19.1% protein, 44.3% carbohydrate and 5.8% fat; LM-485). In some 
experiments, mice were fed the normal chow diet until 8 weeks of age and then switched 
to a high fat diet (HFD; 23.5% protein, 27.3% carbohydrate, and 34.3% fat; TD.06414) or 
an atherogenic diet (AD; 19.7% protein, 40.7% carbohydrate, 15.8% fat, 1.25% 
cholesterol, and 0.5% sodium cholate; TD.88051)). The fatty acid profile of the diets can 
be found in Appendix II. All diets were purchased from Envigo (Indianapolis, IN).   
 
Statin treatment 
Effect of the statin, simvastatin, was assessed in WT and ΔSel1lLiver mice offered 
AD. Eight-week old male WT and ΔSel1lLiver mice received either a daily oral gavage of 
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phosphate-buffered saline (PBS) or progressively increasing doses of simvastatin over an 
8-week period (0.5 mg/kg during weeks 1 - 2, 1 mg/kg during weeks 2 - 4, 2 mg/kg 
during weeks 4 - 6, and 4 mg/kg during weeks 6 - 8). Simvastatin was purchased from 
Merck Sharp and Dohme (Rahway, NJ) and dissolved in PBS. Body mass and survival 
rate were monitored weekly. 
 
Biochemical analyses 
Routine determination of blood glucose involved sampling the tail artery and 
analysis with an Ascensia Contour glucometer (Bayer Health Care; Tarrytown, NY). The 
insulin tolerance test (ITT) was performed in 10-week old mice fed a normal chow diet. 
Briefly, after being fasted for 8 hours, a basal blood sample was obtained from the tail 
artery. This was followed by an ip injection of human insulin (0.75 IU/kg body weight, 
Humulin R, Eli Lilly Co.; Indianapolis, IN) and blood sampling 15, 30, 60, and 120 min 
later.  
Plasma and liver were obtained from 16-week old WT and ΔSel1lLiver mice (n = 5 
per genotype and diet). Liver tissue was homogenized twice in 100 mg/ml PBS with a 
Polytron tissue homogenizer for 30 seconds. The protein concentration of the resulting 
lysate was quantified with the bicinchoninic acid assay (BCA) protein assay kit (Thermo 
Fisher; Waltham, MA). The lysates were mixed with 2:1 chloroform: methanol mixture. 
PBS was then added and the lysates were spun at 1200 g for 5 minutes at 4°C. The 
resulting lower layer consisting of lipids was reconstituted in a 1% triton/ethanol solution 
and assayed for triglyceride, total cholesterol, and total bile acids using commercial kits 
	   118	  
(L-Type Triglyceride M Color-A & L-Type TG M Color-B, Wako Cholesterol E, and 
Total Bile Acids Assay Kit, Wako; Richmond, VA). Plasma was prepared from blood 
samples and analyzed with the same kits for triglyceride, total cholesterol, and total bile 
acids. In addition, alanine transaminase (ALT) was assayed from plasma using a 
commercial kit (Cayman Chemical Company; Ann Arbor, MI). 
 
Histology 
WT and ΔSel1lLiver mice were euthanized at 16 weeks of age (n = 3 per genotype 
and diet). Liver tissues were fixed in 4% paraformaldehyde overnight at 4°C followed by 
dehydration in 95% ethanol overnight at 4°C. Liver sections were then sent to the Cornell 
Core Facility for processing and staining with hematoxylin-eosin (H&E). All 
histologically stained sections were analyzed through an Axiovert 40 Microscope bright 
light microscopy (Carl Zeiss; Oberkochen, Germany) at 10X and 40X magnification. 
 
mRNA extraction and analysis of gene expression 
 WT and ΔSel1lLiver mice were euthanized at 16 weeks of age (n = 8 per genotype). 
Liver tissue was lysed with Qiazol (Qiagen; Hilden, Germany) followed by total mRNA 
purification using RNeasy Mini columns and on-column RNase-free DNase treatment 
(Qiagen; Hilden, Germany). Reverse transcription reactions were performed with 2 µg of 
mRNA in a total 20 µL volume with the SuperScript III Reverse Transcriptase (Thermo 
Fisher; Waltham, MA). Gene expression was analyzed with quantitative real-time PCR 
assays using Power SYBR Green Mix (Applied Biosystems; Foster city, CA). Real-time 
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PCR assays were performed in duplicate with a total 25 µL reaction volume containing 
500 nM concentration of each primer and reverse transcribed mRNA (25 ng except 2.5 
ng for the internal standard gene 18S). The sequences of all primers used are given in 
appendix III. mRNA data were analyzed using the 2-Δ/ΔCt method with 18S expression as 
the internal standard 11.  
 
Western immunoblotting 
Frozen liver tissues from 16-week old WT and ΔSel1lLiver mice (n = 8 per 
genotype) were homogenized in radioimmunopreciptation assay buffer [10 mM tris-HCl 
(pH 7.4), 150 mM NaCl, 1% nonidet P-40, 1 mM phenylmethylsulfonyl fluoride, 1 mM 
EDTA, 1 mM NaF, 0.25% sodium deoxycholate, and 10% glycerol, supplemented with 
HaltTM protease and phosphatase inhibitors (Thermo Fisher; Waltham, MA)]. 
Alternatively, liver samples were processed for preparation of subcellular fractions as 
previously described 12. Briefly, fresh liver tissue was homogenized on ice with a dounce 
pestle in 20% (w/v) organelle purification buffer [250 mM sucrose, 1 mM EDTA pH 7.4, 
2 mM MgCl2, 2 mM KCl, 1 M dithiothreitol (DTT), and HaltTM protease and phosphatase 
inhibitors].  
The homogenate was subjected to 3 rounds of centrifugation (twice at 600 g for 
15 min; twice at 10,000 g for 30 min; once at 100,000 g for 3 h). The pellet collected 
after the final centrifugation was denoted as the microsomal fraction (100,000 g). The 
pellet was solubilized in microsomal buffer [20 mM Imidazole, 5 mM DTT, and 50 mM 
NaCl supplemented with HaltTM protease and phosphatase inhibitors].  
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The protein concentration of liver lysates and microsomal fractions was 
determined using the BCA protein assay.  Samples (20 – 40 µg protein) were separated 
on 5 – 12 % gels and transferred onto polyvinylidene flouride membranes (0.2 µM; Bio-
Rad; Hercules, CA). Membranes were blocked in either 5% non-fat dried skim milk (Bio-
Rad; Hercules, CA) or 2% bovine serum albumin (BSA, Sigma Aldrich; St. Louis, MI) in 
tris-based saline with tween-20 [0.05 M Tris-HCl (pH 7.4), 0.2 M NaCl and 0.1% 
Tween-20].  Membranes were then immunodecorated with primary antibodies against 
human Sel1l (Abcam; Cambridge, United Kingdom), human 3-hydroxy-3-
methylglutaryl-Co A reductase (Hmgcr; Santa Cruz Biotech; Santa Cruz, CA), human 
cytochrome P450, family 7, subfamily a, polpeptide 1 (Cyp7a1; Santa Cruz Bioteh; Santa 
Cruz, CA), human low density lipoprotein receptor (Ldlr; Gene Tex; Irvine, CA), human 
solute carrier family 10 (sodium/bile acid cotransporter family), member 1 (NTCP; Santa 
Cruz Biotech; Santa Cruz, CA), human heat shock protein 90 (Hsp90; Cell Signaling; 
Danvers, MA), human endoplasmic reticulum (ER) to nucleus signaling 1 (IRE1α; Cell 
Signaling; Danvers, MA), human glucose-regulated protein, 78 kDa (Grp78; Cell 
Signaling; Danvers, MA), human synovial apoptosis inhibitor 1, synoviolin  (Hrd1; 
Novus Biologicals; Littleton, CO), and human protein disulfide isomerase (PDI; Cell 
Signaling; Danvers, MA). All primary antibodies were diluted in blocking solution at 
1:1,000 except Cyp7a1, which was diluted at 1:400. Signals were developed with 
1:10,000 dilution of goat anti-rabbit (Thermo Fisher; Waltham, MA) secondary antibody 
and visualized by chemiluminescence (Super Signal West Pico Chemiluminescent 
Substrate, Thermo Fisher; Waltham, MA). 
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Statistical analysis 
Data were analyzed by a mixed model using the fit model procedure of JMP Pro 
11.0 statistical software (SAS Institute; Cary, NC). Data collected over time (growth 
curve, plasma glucose, ITT, and body weight during statin treatment) were analyzed by 
the fit model procedure, which included genotype, time, and their interaction as fixed 
effects and animal as the random effect. Survival curves were compared by the log-rank 
(Mantel-Cox) test. All other variables were analyzed by the fit model procedure, which 
included genotype as the fixed effect and animal as the random effect. The level of 
statistical significance was set at p < 0.05. 
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RESULTS 
Liver-specific deletion of Sel1l in ΔSel1lLiver mice  
Sel1l protein expression was expressed ubiquitously, with the highest level of 
Sel1l protein found in liver, brain, and spleen (Figure 5.1A). ΔSel1LLiver mice were 
generated by crossing Sel1lf/f mice with Sel1l f/f;albumin-Cre mice. To assess liver 
specific deletion, PCR was performed on DNA isolated from various tissues with primers 
flanking exon 6. These primers bracket an 800 bp fragment in WT Sel1l and a 200 bp 
fragment after Cre-mediated recombination (Appendix IV). An expected 800 bp DNA 
fragment was obtained in WT tissues. The smaller fragment of 200 bp was detected only 
in the liver of ΔSel1lLiver mice (Figure 5.1B).  
Finally, Sel1l expression was assessed in the liver of WT and ΔSel1Liver mice. 
Sel1l expression was reduced by 75% at the mRNA level and by 58% at the protein level 
(Figure 5.1C & D; P < 0.001). Together, these observations show selective Sel1l deletion 
in the liver of ΔSel1lLiver mice. 
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A
Sel1l
Hsp90
B C
D
Sel1L
Hsp90
WT ΔSel1lLiver__________________22___________________
WT
800
200
ΔSel1lLiver2____________________22____________________
Figure+5.1+Liver1specific+deletion+of+Sel1l+in+ΔSel1lLiver mice.2(A) Indicated2tissues2were2collected2from2a216Bweek2old2wild2type2
(WT)2mouse.2Total2protein2extracts2were2prepared2and2analyzed2by2western2immunoblotting2for2SelB12suppressor2of2linB12Blike2protein2
(Sel1l)2abundance2and2the2ubiquitous2protein2heat2shock2proteinB902(HSP90).2(B)2Genomic2DNA2was2isolated2from2indicated2tissues2
collected2from2WT2and2ΔSel1lLiver mice2and2analyzed2by2a2PCR2strategy2yielding2an28002bp fragment2for2the2WT2Sel1l2allele2and2a22002
bp fragment2for2the2mutated2allele.2(C)2Total2mRNA2was2isolated2from2liver2tissue2collected2from216Bweek2old2WT2and2ΔSel1lLiver mice2
fed2normal2chow.2Sel1l2mRNA2abundance2was2measured2by2quantitative2real2timeBPCR.2Gene2expression2was2normalized2to218S2
expression.2Sel1l2mRNA2abundance2is2relative2to2WT2level2with2each2bar2representing2the2mean2± SE2of282mice.2***,2P2<20.001.2(D)+
Liver2tissue2was2isolated2from216Bweek2old2WT2and2ΔSel1lLiver mice2fed2normal2chow.2Protein2extracts2were2prepared2from2liver2tissue2
and2analyzed2by2western2immunoblotting2for2Sel1l2abundance.2The2Sel1l2abundance2was2normalized2to2the2heat2shock2protein2902
(Hsp90)2signal2and2expressed2relative2to2WT2level2with2each2bar2representing2the2mean2± SE2of282mice.2***,2P2<20.001.
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Effects of Sel1l ablation in liver on growth and glucose metabolism under normal 
feeding conditions 
 Male mice were fed a normal chow diet and monitored for body weight gain from 
3 to 17 weeks of age. ΔSel1lLiver mice experienced a small reduction in body weight (Figure 
5.2A; Genotype, P < 0.01). This effect appeared to be more prominent between 3 and 8 
weeks of age than at 17 weeks of age. 
Under fed conditions, ΔSel1lLiver mice had lower plasma glucose than WT mice 
(Genotype, P < 0.01). This effect in plasma glucose was more pronounced at 4 and 5 weeks 
of age than between 14 and 17 weeks of age (Figure 5.2B; Genotype x Time, P < 0.05). An 
ITT test was performed at 10 weeks of age. The glucose response area did not differ 
between genotypes (Figure 5.2C).  
 Since Sel1l has been recently shown to play a critical role in lipid metabolism in 
adipose tissue, we next addressed whether Sel1l deletion affected lipid and cholesterol 
metabolism 10. No drastic changes in triglyceride, total cholesterol, or total bile acids were 
observed in ΔSel1lLiver mice when assayed in plasma or liver tissue (Table 5.1). Similarly, 
liver morphology did not differ between WT and ΔSel1lLiver mice when assessed by 
histology (Figure 5.2D). Similar effects were seen in female mice. Accordingly, all 
subsequent studies were performed on male mice. 
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A
C
D
Figure*5.2*Effects*of*Sel1l*ablation*in*liver*on*growth*and*glucose*metabolism*under*normal*feeding*conditions."Male"mice"
harboring"wild"type"Sel1l"(WT)"or"null"Sel1l"in"liver"(ΔSel1lLiver)"were"fed"a"normal"chow"diet"and"studied"between"3"and"17"weeks"of"
age."(A) Growth"curves"representing"the"average"weight"of"individual"mice"from"each"genotype"(n"="11"per"genotype)."The"significant"
effects"of"genotype"and"time"are"reported."(B) Random"glucose"levels"are"shown."Each"curve"represents"the"average"plasma"glucose"
levels"of"individual"mice"from"each"genotype"(n"="10"I12"per"genotype)."The"significant"effects"of"genotype"and"genotype"x"time"are"
reported.""(C) An"insulin"tolerance"test"(ITT)"was"performed"at"10"weeks"of"age."Each"bar"represents"the"mean"± SE"of"the"glucose"
response"area"(n"="5"per"genotype)."(D) HematoxylinIEosin"(H&E)Istained"liver"sections"were"prepared"from"16Iweek"old"mice"(n"="3"
per"genotype)"and"photographed"at"10X"magnification."A"single"representative"photograph"is"shown"for"each"genotype."Scale"bar,"100"
μm.
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Genotype1
WT++++++++++++ ΔSel1lLiver SE++++++++++++++++++++++++++P+Value2++++++++
Plasma
Triglyceride,+mg/dL 58.9 48.5 3.8 NS
Cholesterol,+mg/dL 84.4 117.8 12.4 NS
Total+Bile+Acids,+μM 1.1 1.1 0.4 NS
Liver
Triglyceride,+mg/g+liver 4.7 4.0 0.43 NS
Cholesterol,+mg/g+liver 3.5 2.9 0.19 NS
Total+Bile Acids,+μM/g+liver 190.0 249.3 37.4 NS
Table&5.1&Effect+of+liverPspecific+ablation+of+Sel1l+in+mice+fed+a+normal+chow+diet+on+metabolic+variables
1Male+mice+harboring+wild+type+(WT)+or+null+Sel1l+in+liver+(ΔSel1lLiver)+were+fed+a+normal+chow+diet+and+studied+at+16+weeks+of+age+
(n+=+5+per+genotype).+
2Type+I+error+probability+for+genotype.+NS,+nonPsignificant+at+P+≥+0.05.
________________________
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Effects of Sel1l deletion in liver on ER Stress under normal feeding conditions 
Perturbations in ER homeostasis have been observed in several Sel1l mouse 
models 7,10,13,14. We next addressed whether ER homeostasis was altered in liver of 
ΔSel1lLiver mice fed normal chow diet by measuring mRNA levels of several ER stress 
markers. Sel1l ablation increased the expression of the DnaJ heat shock protein family 
(Hsp40) member C3 (p58IPK), Hrd1, homocysteine-inducible endoplasmic reticulum 
stress-inducible, ubiquitin-like domain member 1 (Herp), stress-associated endoplasmic 
reticulum protein 1 (RAMP4), spliced variant x-box binding protein-1 (Xbp1S), DNA-
damage inducible transcript 3 (Chop), Grp78, and DnaJ heat shock protein family 
(Hsp40) member B11 (ERdj3) (P < 0.05 or less). Expression of gamma-aminobutyric 
acid (GABA) A receptor subunit alpha-1 (Gabra1), a non-UPR-related gene, was not 
altered between genotypes (Figure 5.3A). Protein expression of Grp78 and IRE1α were 
increased in liver of ΔSel1lLiver mice (P < 0.05), whereas no effect was observed on Hrd1 
and PDI (Figure 5.3B). Accordingly, ER stress is activated in the liver of ΔSel1lLiver 
mice. 
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Hrd1
PDI
Hsp90
Grp78
IRE1α
WT ΔSel1lLiver;___________________;;___________________
Figure)5.3)Effects)of)Sel1l)deletion)in)liver)on)ER)Stress)under)normal)feeding)conditions.;Male;mice;harboring;wild;type;Sel1l;
(WT);or;null;Sel1l;in;liver;(ΔSel1lLiver);were;fed;a;normal;chow;diet;and;studied;at;16;weeks;of;age.;(A))Total;mRNA;was;analyzed;by;
quantitative;realTtime;PCR;for;expression;of;genes;indicative;of;DnaJ heat;shock;protein;family;(Hsp40);member;C3;(p58IPK),;synovial;
apoptosis;inhibitor;1,;synoviolin (Hrd1),;homocysteineTinducible;endoplasmic;reticulum;stressTinducible,;ubiquitinTlike;domain;member;
1;(Herp),;stressTassociated;endoplasmic;reticulum;protein;1 (RAMP4),;spliced;variant;xTbox;binding;protein;1;(XBP1s),;DNATdamage;
inducible;transcript;3;(Chop),;glucoseTregulated;protein,;78;kDa (Grp78),;and;DnaJ heat;shock;protein;family;(Hsp40);member;B11;
(ERdj3).;GammaTaminobutyric;acid;(GABA);A;receptor;subunit;alphaT1 (Gabra1);mRNA;was;measured;as;a;nonTER;stress;gene.;
Gene;expression;was;normalized;to;18S;expression.;The;expression;of;each;gene;is;relative;to;WT;level;with;each;bar;representing
the;mean;± SE;of;8;mice.;*,;P;<;0.05,;**,;P;<;0.01,;***,;P;<;0.001.;(B))Protein;extracts;were;prepared;from;liver;and;analyzed;by;
western;immunoblotting;for;Grp78,;endoplasmic;reticulum;(ER);to;nucleus;signaling;1;(IRE1α),;Hrd1,;and;protein;disulfide;isomerase;
(PDI);abundance.;Protein;expression;was;normalized;to;the;heat;shock;protein;90;(Hsp90);signal.;The;abundance;of;each;protein;is;
relative;to;WT;level;with;each;bar;representing;the;mean;± SE;of;8;mice.;*,;P;<;0.05.
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Effect of high fat diet on growth and metabolic variables of ΔSel1lLiver mice  
Mice were switched from a normal chow diet to a HFD at 8 weeks of age and 
studied for the next 9 weeks. As previously observed on a normal chow diet, ΔSel1lLiver 
mice suffered a slight growth deficit (Figure 5.4A; Genotype, P < 0.01). There was no 
genotype x time interaction indicating that the HFD did not exacerbate the growth deficit 
of ΔSel1lLiver mice. ΔSel1lLiver mice suffered lower plasma glucose (Genotype, P < 0.001) 
until week 13 of life, which then rose to levels comparable to WT mice thereafter (Figure 
5.4B; Genotype x Time, P < 0.001).  
We also asked whether the HFD impacted lipid and cholesterol metabolism. No 
genotype effects were seen for triglyceride or total bile acids when assayed in plasma or 
liver tissue (Table 5.2). In contrast, ΔSel1lLiver mice exhibited a significant increase in 
total cholesterol in plasma (P < 0.05), but not liver. By liver histology, ΔSel1lLiver mice 
appeared to have fewer hepatic lipid droplets than WT mice (Figure 5.4C). 
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Figure*5.4*Effect*of*high*fat*diet*on*growth*and*metabolic*variables*of*ΔSel1lLiver mice."Male"mice"harboring"wild"type"Sel1l"(WT)"
or"null"Sel1l"in"liver"(ΔSel1lLiver)"were"fed"high"fat"diet"(HFD)"between"8"and"17"weeks"of"age."(A) Growth"curves"are"shown."Each"curve"
represents"the"average"weight"of"individual"mice"from"each"genotype"(n"="15"per"genotype)."The"significant"effects"of"genotype"and"
time"are"reported."(B) Random"glucose"levels"are"shown."Each"curve"represents"the"average"plasma"glucose"levels"of"individual"mice"
from"each"genotype"(n"="8"L11"per"genotype)."The"significant"effects"of"genotype,"time,"and"genotype"x"time"are"reported."(C)*Livers"
were"collected"at"16"weeks"of"age"and"analyzed"by"hematoxylinLeosin"(H&E)Lstaining"(n"="3"per"genotype)."All"liver"sections"were
photographed"at"10X"magnification."A"single"representative"photograph"is"shown"for"each"genotype."Bar"scale,"100"μm.
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Genotype1
WT++++++++++++ ΔSel1lLiver SE++++++++++++++++++++++++++P+Value2++++++++
Plasma
Triglyceride,+mg/dL 224.2 241.2 33.3 NS
Cholesterol,+mg/dL 93.7 128.3 7.5 0.02
Total+Bile Acids,+μM 2.2 2.3 0.26 NS
Liver
Triglyceride,+mg/g+liver 15.6 17.4 2.9 NS
Cholesterol,+mg/g+liver 10.1 10.3 0.8 NS
Total+Bile Acids,+μM/g+liver 91.9 94.7 7.6 NS
_______________________
Table&5.2 Effect+of+high+fat+diet+on+growth+and+metabolic+variables+of+ΔSel1lLiver mice+
1Male mice harboring wild type (WT) or null Sel1l in liver (ΔSel1lLiver) were fed a high fat diet between 8 and 17 weeks of age (n = 3 per genotype). 
Mice were studied at 16 weeks of age.
2Type I error probability for genotype. NS, non-significant at P ≥ 0.05. *, significant when P < 0.05. 
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Effect of atherogenic diet on growth and survival of ΔSel1lLiver mice 
To address further the possibility that Sel1l plays a role in hepatic lipid 
metabolism, mice were switched from a normal chow diet to the AD at 8 weeks of age. 
Body weights were comparable at 8 weeks of age, but a growth deficit became obvious in 
ΔSel1lLiver mice by week 12 (Figure 5.5A). Between 8 and 16 weeks of age, WT mice 
gained an average of 3.7 g, whereas ΔSel1lLiver mice lost 5.6 g (Genotype x Time, P < 
0.001). By week 16, WT mice weighed 24.3 g, versus 12.8 g for ΔSel1lLiver mice 
(Genotype, P < 0.001). Moreover, mortality was observed in a subset of ΔSel1lLiver mice, 
whereas no such effect was seen in WT mice (Figure 5.5B).  
At the end of treatment, the liver was larger and paler in ΔSel1lLiver mice than WT 
mice. In line with this observation, the liver to body weight ratio increased by 47% in 
ΔSel1lLiver mice (Figure 5.5C; P < 0.01). By H&E histology, hepatocytes in ΔSel1lLiver 
mice appeared enlarged and “balloon-shaped” (Figure 5.5D). Finally, plasma ALT levels 
increased by 91% in ΔSel1lLiver mice when compared to WT mice, suggesting liver 
damage (Figure 5.5E; P < 0.001). Thus, our data shows that ΔSel1lLiver mice are 
intolerant to AD, resulting in liver damage and occasional death. 
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Figure+5.5+Effect+of+the+atherogenic diet+on+growth+and+survival+of+ΔSel1lLiver mice.+Male%mice%harboring%wild%type%Sel1l%(WT)%or%
null%Sel1l%in%liver%(ΔSel1LLiver)%were%fed%an%atherogenic diet%between%8%and%16%weeks%of%age.%(A) Growth%curves%of%each%genotype%(n%=%
10%G13%per%genotype).%The%significant%effects%of%genotype%and%genotype%x%time%are%reported. (B)+Survival%curves%of%each%genotype%(n%=%
10%G 13%per%genotype).%(C) Appearance%and%fractional%weight%of%liver%in%16Gweek%old%mice.%Each%bar%represents%the%mean%± SE%of%7%– 10%
mice.%**,%P%<%0.01.%(D).%HematoxylinGeosin%(H&E)Gstained%liver%sections%from%16Gweek%old%mice%(n%=%3%per%genotype)%were%photographed%
at%10X%magnification%and%40X%magnification%(bottom%left%hand%corner).%A%single%representative%photograph%is%shown%for%each%genotype.%
Scale%bar,%100%μm.%(E) Plasma%alanine%transaminase%(ALT)%content%was%measured%in%16Gweek%old%mice.%Each%bar%represents%the%mean%
± SE%of%5%mice.%***,%P%<%0.001.
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Effect of atherogenic diet on hepatic cholesterol metabolism in ΔSel1lLiver mice 
We next asked whether alterations in cholesterol metabolism accounted for 
abnormal liver parameters in ΔSel1lLiver mice fed an AD diet. Total cholesterol levels 
increased by 63% in plasma and by 54% in liver in ΔSel1lLiver mice (Figure 5.6A; P < 
0.001). We then focused on mechanisms that could account for abnormally elevated 
cholesterol in plasma and liver of ΔSel1lLiver mice. We measured the liver mRNA and 
protein levels of Hmgcr, the rate-limiting enzyme for endogenous cholesterol synthesis. 
Hmgcr mRNA and protein levels were increased in ΔSel1lLiver mice (Figure 5.6B & data 
not shown; P < 0.001). These data suggest that the liver is unable to reduce cholesterol 
synthesis in absence of Sel1l. 
To test this possibility, we asked whether simvastatin could rescue ΔSel1lLiver 
mice. Simvastatin reduces endogenous cholesterol synthesis by exhibiting a higher 
binding affinity to Hmgcr than HMG-CoA 15. WT and ΔSel1lLiver mice were fed AD 
between 8 and 16 weeks of age and treated concurrently with either PBS or simvastatin 
solution. In WT mice, there was no difference in body weight between control and 
simvastatin groups (Figure 5.6C). As before, ΔSel1lLiver mice lost body weight over time 
(Genotype x time, P < 0.001) and simvastatin was unable to prevent this effect. Similarly, 
simvastatin was unable to normalize the liver to body weight ratio of ΔSel1lLiver mice to 
that of WT mice (Figure 5.6D) ΔSel1lLiver mice.  
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Figure+5.6+Effect+of+the+atherogenic diet+on+hepatic+cholesterol+metabolism+in+ΔSel1lLiver mice.3Male3mice3harboring3wild3type3
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prepared3from316Qweek3old3mice3were3analyzed3by3western3immunoblotting3for33QhydroxyQ3QmethylglutarylQCo3A3reductase3(Hmgcr)3
abundance.3Protein3expression3was3normalized3to3the3heat3shock3protein3903(Hsp90)3signal.3The3abundance3of3each3protein3is3relative3
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end3of3treatment3(n3=363per3genotype3and3treatment).3The3significant3effect3of3genotype3is3reported.
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Effect of atherogenic diet on hepatic lipid metabolism and low-density lipoprotein 
receptor in ΔSel1lLiver mice  
Next, we asked whether deletion of Sel1l in liver tissue led to alterations in lipid 
metabolism. The plasma of ΔSel1lLiver mice was “butter-like” yellow and viscous, unlike 
the clear, fluid appearance of WT plasma (Figure 5.7A), suggesting elevated lipid levels. 
Moreover, triglyceride was increased 84% in plasma and 67% in liver in ΔSel1lLiver mice 
(Figure 5.7B; P < 0.001). These data suggest that ΔSel1lLiver mice exhibit defects in lipid 
metabolism.  
Ldlr is a plasma membrane glycoprotein primarily expressed in liver that is 
critically required for uptake and metabolism of the circulating lipoproteins intermediate-
density lipoprotein (Idl) and low-density lipoprotein (Ldl) 16.  Genetic deficiency of Ldlr 
in humans and in mice has been implicated in the pathogenesis of hypercholesterolemia 
17. To assess this, we investigated whether hepatic Ldlr contributes to altered lipid and 
cholesterol homeostasis in ΔSel1LLiver mice. Hepatic mRNA and protein levels of Ldlr 
were reduced in ΔSel1lLiver mice (P < 0.001 & Data not shown). In addition, ΔSel1lLiver 
mice displayed reduced hepatic Ldlr protein levels in microsomal fractions (Figure 5.7C; 
P < 0.001). Taken together, these data suggest that ΔSel1lLiver mice have abnormally low 
levels of hepatic Ldlr.  
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Figure*5.7*Effect*of*the*atherogenic diet*on*hepatic*lipid*metabolism*and*low=density*lipoprotein*receptor*in*ΔSel1lLiver*mice.*
Male3mice3harboring3wild3type3Sel1l3(WT)3or3null3Sel1l3in3liver3(ΔSel1lLiver)3were3fed3the3atherogenic diet3between383and3163weeks3of3
age.3(A) Plasma3was3prepared3at3the3time3of3sacrifice3(n3=353per3genotype).3A3single3representative3photograph3of3plasma3is3shown3for3
each3genotype.3(B) Triglyceride3was3measured3in3plasma3and3liver3(n3=353per3genotype).3Each3bar3represents3the3mean3± SE.3***,3P3<3
0.001.3(C) Protein3extracts3were3prepared3from3liver3and3analyzed3by3western3immunoblotting3for3lowTdensity3lipoprotein3receptor3(Ldlr)3
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was3normalized3to3the3calnexin signal.3Two3representative3samples3are3shown3for3every3subcellular3fraction.33The3abundance3of3Ldlr is3
relative3to3WT3level3with3each3bar3representing3the3mean3± SE3of363mice.3***,3P3<30.001.
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ΔSel1lLiver mice exhibit defects in bile acid metabolism 
Sel1l was recently identified in a genome wide association study as a candidate 
gene in controlling the plasma concentration of total bile acid 18. This led us to ask 
whether ΔSel1lLiver mice fed the AD diet would have altered bile acid metabolism. 
ΔSel1lLiver mice exhibited a 91% increase in total bile acids when assayed in plasma (P < 
0.001), whereas no such effect was observed in liver (Figure 3.8A). 
We then focused on mechanisms that could account for abnormally elevated total 
bile acids in plasma of ΔSel1lLiver mice. In liver tissue, we measured the protein 
abundance of the rate-limiting enzyme of bile acid synthesis (Cyp7a1) and of NTCP a 
transporter protein involved in the reuptake of plasma bile acids in liver respectively. 
Cyp7a1 was decreased (P < 0.01), whereas NTCP was not altered in ΔSel1lLiver mice 
(Figure 5.8B). These data suggest defects in bile acid metabolism in absence of Sel1l in 
liver. 
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DISCUSSION 
Cells actively involved in the synthesis and secretion of proteins utilize the ERAD 
system to target mis-folded or improperly assembled proteins for proteasomal 
degradation 19. Sel1l has been identified as an indispensable component of the ERAD 
system involved in maintaining ER homeostasis 7. Sel1l is known to form a 1:1 
stoichiometric complex with Hrd1 within the ERAD system 20. Sel1l, however, is six-fold 
more abundant than Hrd1, leading to the speculation that it is involved in roles 
independent of the ERAD system 21. Until recently, however, the only evidence 
suggestive of an ERAD system-independent role of Sel1l was provided by mice with 
adipose-specific ablation. In these mice, Sel1l was found to be essential for lipoprotein 
lipase maturation and storage of lipid in adipose tissue 10.  These observations led us to 
ask whether deletion of Sel1l in hepatocytes would impact lipid homeostasis.  
We first validated that Sel1l mRNA and protein abundance in liver were 
significantly decreased in ΔSel1lLiver mice. As anticipated from other tissue-specific Sel1l 
knockout mouse models 7,10,13, hepatic Sel1l ablation was associated with substantial 
increases in markers of ER stress. When placed on a normal chow diet, ΔSel1lLiver mice 
exhibited a slight growth deficit and decreased plasma glucose levels during the first few 
weeks of life, but did not have any alterations in lipid metabolism 10. Feeding a HFD 
resulted in similar effects on growth and early life glycemia, but also led to increased 
plasma cholesterol levels, suggesting a role for liver Sel1l in lipid metabolism.  
To probe this role further, mice were offered an AD diet between 8 and 16 weeks 
of life. AD is frequently used to amplify defects in lipid metabolism and is particularly 
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effective in altering the plasma lipoprotein profile in mice. For example, Ldlr knockout 
mice fed AD experienced reduced high-density lipoprotein (HDL) and increased very 
low-density lipoprotein (Vldl), Idl, and Ldl in plasma 22.  
As expected, the AD revealed major defects in the lipid metabolism of ΔSel1LLiver 
mice. Specifically, AD feeding to ΔSel1lLiver mice led to a pale and enlarged liver with 
‘balloon-shaped’ hepatocytes and increased the plasma levels of the marker of liver 
damage, ALT. ΔSel1lLiver mice suffered from increased levels of triglyceride and 
cholesterol in liver and plasma.  
We first attempted to understand the basis for increased liver and plasma 
cholesterol in ΔSel1lLiver mice. Hmgcr has been previously implicated as a critical 
enzyme of cholesterol homeostasis in liver 23,24. This enzyme is normally down regulated 
when dietary cholesterol is in excess. Indeed, feeding AD to WT mice suppressed the 
mRNA expression of genes involved in cholesterol biosynthesis including Hmgcr 25. 
Surprisingly, our data showed increased Hmgcr protein expression in ΔSel1lLiver mice fed 
AD, suggesting loss of the cholesterol negative feedback. To test this mechanism in a 
functional manner, we asked whether statins could rescue the growth phenotype and 
mortality of ΔSel1lLiver mice. Statins are a class of pharmacological drugs that repress 
cholesterol synthesis by competing HMG-CoA binding to Hmgcr 26. Treatment of 
ΔSel1lLiver mice fed AD with statins, however, did not correct the phenotype of 
ΔSel1lLiver mice. An important question that was not addressed is whether statin 
normalized plasma and liver TG and cholesterol levels in ΔSel1lLiver mice.  
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A second possible contributor to abnormal lipid metabolism of ΔSel1lLiver mice 
could be inappropriate hepatic uptake of lipoproteins. The Ldlr is involved in the uptake 
of lipoprotein-enriched cholesterol molecules [chylomicron remnants, Idl, and Ldl] 24. 
Mice with targeted disruption of Ldlr experienced significant increases in plasma 
cholesterol in absence of changes in plasma triglyceride when placed on AD 27. This 
phenotype was due to decreased clearance of plasma chylomicron remnants, Vldl, Idl, 
and Ldl from the circulation 27,28. As shown by our data, ΔSel1lLiver mice fed AD 
exhibited decreased hepatic Ldlr mRNA and protein abundance, suggesting that this 
defect contributes to their increased plasma cholesterol. Deficiency in Ldlr, however, 
may not be solely responsible as liver also removes chylomicron remnants, Idl, and Ldl 
via another receptor known as low density lipoprotein-related protein (LRP) 29. LRP can 
increase uptake of lipoproteins when Ldlr is downregulated or absent 30. Unlike Ldlr, 
LRP abundance is not subject to cholesterol negative feedback 31. Mice with targeted 
deletion of LRP in liver experienced increased plasma total cholesterol, reflecting an 
increase of plasma lipoproteins 32. It will be important in future work to determine the 
impact of ΔSel1lLiver mice on all possible lipoprotein receptors as well as impact on the 
profile of circulating lipoproteins.  
Another critical factor to consider in explaining the abnormal lipid phenotype of 
ΔSel1lLiver mice involves defective machinery involved in lipoprotein hydrolysis. For 
example, hepatic lipase is a lipolytic enzyme in liver that is synthesized, processed, and 
secreted from the ER 33. It is primarily found in the circulation, but also localizes on the 
surface of hepatocyte sinusoid capillaries. Hepatic lipase exerts a hydrolytic effect on 
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triglyceride present in Vldl, promoting its conversion to Idl or Ldl in circulation 34. Rat 
livers perfused with hepatic lipase antibodies have reduced hepatic uptake of triglycerides 
35. Humans with loss of function mutations of hepatic lipase were predisposed to 
hyperlipidemia 36. In contrast, transgenic mice overexpressing hepatic lipase showed 
reduced plasma Ldl on a normal chow diet and reduced plasma Vldl, Idl, and Ldl on a 
HFD 37. As Sel1l was previously shown to be essential for secretion of mature lipoprotein 
lipase from adipose tissue, it may play a similar role for hepatic lipase secretion from 
liver.  
Conversion of excess cholesterol to bile acids is a mechanism whereby 
cholesterol homeostasis is maintained 38. Accordingly, diets with excessive cholesterol 
and cholic acid can induce alterations in bile acid homeostasis 39. Interestingly, dogs with 
a missense mutation in Sel1l (S658P) exhibit increased levels of plasma total bile acid  18. 
Very recently, a genome wide association study (GWAS) was performed on C57BL/6J-
chr12A/J/NaJ consomic mice fed the AD in order to identify loci influencing liver-related 
metabolic phenotypes. Through this study, Sel1l was identified as a mediator of bile acid 
homeostasis 18.  C57BL/6J-chr12A/J/NaJ consomic mice on the AD showed decreased 
Sel1l protein expression, increased plasma total bile acids, and increased plasma 
cholesterol when compared to C57Bl/6 control mice 18. We found similar results of 
increased total bile acid in plasma of ΔSel1lLiver mice fed AD.  
Hepatocyte basolateral bile acid transporters are responsible for hepatic reuptake 
of bile acids from the enterohepatic circulation. Wu et al observed a significant decrease 
in hepatocyte basolateral bile acid transporters including NTCP and solute carrier family 
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22 (organic anion transporter), member 7 (slc22a7) by feeding AD to C57BL/6J-
chr12A/J/NaJ consomic mice 18. In contrast, we observed no differences in NTCP 
abundance in liver of ΔSel1lLiver mice fed AD. Further experiments are required to 
determine if additional bile acid transporters including slc22a7 are altered in ΔSel1lLiver 
mice. 
Increasing evidence continues to support that chronic hypercholesterolemia is a 
contributor to the onset of metabolic diseases including fatty liver, hepatic steatosis, and 
atherosclerosis 17,40,41. Our findings therefore have potential therapeutic implications. To 
the best of our knowledge, this is the first direct evidence of a role for hepatic Sel1l in 
regulating lipoprotein metabolism. Further studies are required to gain a more complete 
understanding of the molecular mechanisms linking Sel1l, lipid, and cholesterol 
homeostasis. 
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Part I: Adiponectin 
The mammary gland of early lactating (EL) dairy cows uses over 80% of the 
whole animal glucose flux. A key mechanism promoting mammary glucose utilization 
during this period is insulin resistance (IR) 1–3. However, we know surprisingly little 
about factors responsible for the development of IR in transition dairy cows. We and 
others have demonstrated a sudden drop in the plasma concentration of the insulin-
sensitizing hormone adiponectin between late pregnancy (LP) and EL in transition dairy 
cows 4–6. However, factors regulating the periparturient drop in plasma adiponectin 
remain unknown. 
 In our first experiment, we assessed whether metabolic and hormonal factors [i.e. 
energy balance, adiposity, insulin, growth hormone (GH), and non-esterified fatty acids 
(NEFA)] previously shown to regulate adiponectin in rodents and humans, contribute to 
the variation in plasma adiponectin in transition dairy cows. Dairy cows dried off at 
parturition and remaining in positive energy balance maintained higher plasma 
adiponectin than lactating cows in negative energy balance (NEB). This study also 
showed that the periparturient recovery of plasma adiponectin occurred independently of 
changes in adiposity. Increasing circulating levels of leptin, insulin, GH, and NEFA did 
not have any effects on plasma adiponectin. 
We previously demonstrated that the periparturient drop in plasma adiponectin in 
dairy cows occurred in absence of changes in adiponectin mRNA. In rodents, adiponectin 
oligomer assembly is coordinated by a subset of endoplasmic reticulum (ER) chaperone 
proteins [i.e. glucose-regulated protein, 78 kDa (Grp78), endoplasmic reticulum protein 
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44 (Erp44), endoplasmic reticulum oxidoreductase α (ERO1-La), protein disulfide 
isomerase associated 6 (Pdia6), disulfide bond A oxidoreductase-like protein (DsbA-L), 
and gamma adaptin ear containing, ARF binding protein 1 (Gga1)] 7,8. ER chaperone 
expression is in part coordinated by the master regulator of ER homeostasis x-box 
binding protein 1 (Xbp1) 9,10.  Xbp1 increased plasma adiponectin by raising ER 
chaperone expression in white adipose tissue (WAT) of mice 11. In dairy cows, several 
ER chaperone proteins (i.e. Grp78, Erp44, and Pdia6) are reduced in WAT during EL.  
These data led us to hypothesize in our second experiment that Xbp1 is decreased in 
white adipose tissue (WAT) in EL and that this reduction accounts for decreased ER 
chaperone expression and adiponectin production. We showed that Xbp1 was decreased 
in WAT of EL dairy cows. Using a primary bovine adipocyte system, we assessed 
whether Xbp1 impacted ER chaperone expression and adiponectin production and 
secretion. Raising Xbp1 expression increased several ER chaperones including Grp78, 
Erp44, and Pdia6, but had no effect on adiponectin mRNA or secretion in media. Next, 
we assessed whether other factors regulating adiponectin in other species [exogenous 
lipid, tumor necrosis factor a (TNFa), and GH] were involved in bovine adipocytes, and 
if the case, whether the effect related to ER chaperone regulation. TNFa and absence of 
exogenous lipid reduced adiponectin secretion, but these effects were not associated with 
changing ER chaperone expression. Similar to our work in dairy cows (Chapter 3), GH 
had no effect on adiponectin mRNA or secretion in media in bovine adipocytes. 
In rodents and humans, adiponectin production and secretion varies between 
adipose tissue depots (i.e. visceral vs. subcutaneous). For example, adiponectin secretion 
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from human adipose tissue is higher in the visceral depot, than the subcutaneous fat depot 
after treatment with thiazolidinedione 12. Another study suggested that subcutaneous 
white adipose tissue (scWAT) accounts for only 8% of plasma adiponectin in human 
subjects 13. In the mouse, the contribution of scWAT was inferred to be 30% based on 
studies of a transgenic mouse model lacking scWAT 14.  However, studies in dairy cows 
are limited to scWAT, due to difficulty of obtaining biopsies from other adipose tissue 
depots. Adiponectin protein abundance measured between adipose tissue depots (visceral 
and subcutaneous) increased in a similar manner across lactation in dairy cows in absence 
of changes in adiponectin mRNA 15,16. However, it is important to note that this 
experiment did not measure adiponectin mRNA and protein abundance from various 
adipose tissue depots in transition dairy cows during LP. Future mechanistic studies 
involving the periparturient drop and recovery of plasma adiponectin in transition dairy 
cattle need to consider other major fat depots.  
In rodents and humans, prolonged calorie restriction and/or weight loss increase 
plasma adiponectin in absence of changes in both adiponectin expression and secretion 
from adipose tissue 17,18. Transplanting adipose tissue into fat-less A-ZIP/F-1 mice 
increased plasma leptin, but had little effect on adiponectin 19. Additional sources of 
adiponectin other than adipose tissue must therefore regulate its plasma concentration. 
Bone marrow adipose tissue (MAT) has been suggested to produce and secrete 
adiponectin in mice, rabbits, and humans 20. Detectable adiponectin mRNA and protein 
were reported in vivo (i.e. mouse and human bone marrow) and ex vivo (i.e. rabbit and 
human MAT explants) 20–23. Primary bone marrow adipocytes isolated from rabbit and 
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human bone marrow secrete adiponectin 20. Two independent groups developed an ex 
vivo system to culture adipocytes derived from bone marrow of fetal calves 24,25. 
Unfortunately, both studies did not assess adiponectin production or secretion. Future 
studies should be performed to determine whether MAT contributes to the quadratic 
variation of plasma adiponectin in the periparturient dairy cow. 
 
Part II: Sel1l 
 The liver is an extraordinarily efficient organ in terms of synthesis and secretion 
of both proteins and lipids. Accordingly, sustaining endoplasmic reticulum (ER) 
homeostasis is critical for secretory cells. Imbalances in ER function occur in secretory 
cells undergoing increased synthesis 26. Cells therefore rely on key quality control 
systems including the unfolded protein response (UPR) and endoplasmic reticulum-
associated degradation (ERAD) to maintain ER homeostasis under conditions of induced 
stress 27. A myriad of liver diseases including fatty liver and cholestasis are associated 
with increased activation of UPR and ERAD 28,29. Recent evidence implicated the ERAD 
transmembrane protein sel-1 suppressor of lin 12-like protein (Sel1l) in maintaining lipid 
homeostasis in adipose tissue  30. 
 In this work, we assessed whether Sel1l plays a similar role in sustaining lipid 
homeostasis in liver. To this end, we generated an experimental mouse model whereby 
Sel1l was specifically ablated in liver (DSel1lLiver). On a normal chow diet, DSel1lLiver 
mice showed a slight growth deficit during the first few weeks of life. DSel1lLiver mice did 
not exhibit defective indices of lipid metabolism, despite exhibiting increased expression 
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of ER stress markers. DSel1lLiver mice placed on a HFD showed a slight growth deficit. 
When placed on an atherogenic diet (AD),  DSel1lLiver mice exhibited hepatomegaly with 
‘ballooned’ hepatocytes, increased triglyceride, and cholesterol in liver and plasma, and 
total bile acid in plasma. Although this study provides unambiguous evidence of Sel1l 
playing a role in lipid metabolism in liver, the exact mechanisms are still unknown.  
 Future studies on DSel1lLiver mice could focus on the profile of circulating 
lipoproteins. This profile would help to identify factors accounting for 
hypertriglyceridemia and/or hypercholesterolemia in plasma and narrow down possible 
hepatic pathways affected by absence of Sel1l. Mouse models exhibiting defects in lipid 
metabolism are characterized by changes in the lipoprotein profile compared to healthy 
controls. For example, Ldlr knockout (DLdlr) mice fed an AD showed increased 
intermediate-density lipoprotein (Idl), low-density lipoprotein (Ldl), and very low-density 
lipoprotein (Vldl), and decreased high-density lipoprotein (Hdl) 31. Humans, non-human 
primates and other species suffering from hypercholesterolemia showed increased Vldl, 
Idl, and/or Ldl 32. Measurement of circulating lipoproteins should therefore be performed 
as a first step to understand the defects in lipid metabolism of DSel1lLiver mice fed AD. 
Rodent models of hepatic steatosis showed increased expression of transcription 
factors and enzymes involved in de novo lipogenesis 33. Increased ER stress was 
previously linked to increased hepatic lipogenesis in mice 34. Sha et al reported that 
elevated plasma triglyceride and hepatic lipids were associated with increased expression 
of lipogenic genes in liver of  DSel1lAdipose  mice on a high fat diet 30. It will be important 
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in future studies to address the possibility that increased hepatic lipogenesis contributes to 
the hypertriglyceridemia of DSel1lLiver mice fed AD.  
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Gene1 Sequence2                                                     Product (bp)             Accession No.
Fabp4
F     TGCACTTCTTTCTCACCTTGA
R     CAGCCACTTTCCTGGTAGC
150 NM_174314.2
Leptin
F TCACCAGGATCAATGACATCTCA
R     ACCAGTGACCCTCTGTTTGGA
96 NM_173928.2
Adiponectin
F GTGGCTCTGATTCCACACCT
R GCCATGACTGGGTAAGGCTA
83 NM_174742.2
Erp44
F     TGATTGTGCCTTCCTAGCTGCGT
R ATCTGGAGCAGAATGCCCTGGTG
100 NM_001035032.2
ERO1-Lα
F     CTACAAGTATTCTGAAGAAGCC
R CTCACTCAGAGATTCATCCA
88 NM_001103348.1
Pdia6
F     ACCAGGTTCTCGCCAGCCGAT
R TGCGTCCCCCGTCGTAATCCA
96 NM_001206345.1
Grp78 
F     CATCACGCCGTCTTATGTGG
R     GGTGAGCTGGTTCTTGGCTG
76 NM_001075148.1
DsbA-L
F CTCCGACCGGCTGGAGTTGC
R GGCACAGGGCCCATCCACTT
60 NM_001079616.2
Gga1
F     GGCCAGCATCAACGGCTTCTGTG
R     TCCTGCGGGGACTGGATCTTGT
99 NM_001035408.1
Xbp1T
F     TTGTCACCCCTCCAGAACATC
R     TCCAAGTTGAACAGAATGCCC
97 NM_001034727.3
Appendix I. Bovine primers used in real-time PCR analysis
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1Primers(were(designed(to(measure(the(abundance(of(fatty(acid(binding(protein(4((Fabp4),(leptin,(adiponectin,(
endoplasmic(reticulum(resident(protein(44((Erp44),(endoplasmic(reticulum(oxidoreductase(1?like(α((ERO1?Lα),(protein(
disulfide(isomerase(family(associated(6((Pdia6),(glucose?regulated(protein,(78(kDa (Grp78),(glutathione(S?transferase(
kappa(1((DsbA?L),(golgi associated,(gamma(adaptin ear(containing,(ARF(binding(protein(1((Gga1),(x?box(binding(
protein(1(total((Xbp1T),(spliced(variant(Xbp1((XBP1S),(and(18S(ribosomal(RNA((18S).(
2Primer(sequences(are(shown(in(a(5’(to(3’(orientation.
Xbp1S
F     TGCTGAGTCCGCAGCAGG
R     CATCAGAGTCCATGGGGAGA
94 NM_001271737.1
18S
F     GATCCATTGGAGGGCAAGTCT
R GCAGCAACTTTAATATACGCTATTGG
74 NR_036642.1
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Normal'chow'''''''' High'fat'diet'''''''''Atherogenic diet
(LM7485)'''''''''' (TD.06414)'''''''''''''(TD.88051)
Fatty acids'(g/kg)
14:0'Myristic 7 4.7 7
16:0'Palmitic 0.6 80.2 19.4
18:0'Stearic 0.2 39.3 25.9
18:1'Oleic 1.3 146.8 26.5
18:2'Linoleic 2.6 47.0 17.6
18:3'Linolenic 0.3 5.5 1.28
16:1'Palmitoleic 7 9.6 0.23
20:0'Arachidic 7 94.7 0.83
Saturated'fatty'acid 0.8 124.8 74.0
Monounsaturated'fatty'acid 1.3 160.5 55.7
Polyunsaturated fatty'acid 2.9 54.0 20.4
n73 7 7 1.28
n76 7 7 17.6
Appendix(II. Fatty'acid'profile'of'diets
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Gene1 Sequence2                                                   Product (bp)    Accession No.
Sel1l
F     GATGAGTGCACCTCAGACGG
R     TGCTTCCTGCATCTGTCGTC
135 NM_001039089.1
p58IPK
F     TTGACGGTGCCGATTACACT
R     CATTCTGCTCGCAGTTCACG
97 NM_008929
Hrd1
F     AGCTACTTCAGTGAACCCCACT
R CTCCTCTACAATGCCCACTGAC
169 NM_001164709
Herp
F     TCATGGGTGCCACTGTAGTC
R     AGCATCTCGAGGACCACCAT
104 NM_022331.1
RAMP4
F     AGAAAAGGCGTCGGTAGGAC
R     TCAGTCACTTCACATGCCCA
112 NM_030685.3
Xbp1S
F     AACAGAGTAGCAGCGCAGAC
R     AGGATCCAGCGTGTCCATTC
195 NM_001271730.1
Chop
F     ATGTTGAAGATGAGCGGGTGG
R     GCTTTCAGGTGTGGTGGTGTA
109 NM_007837
Grp78
F     GATCAGCGGGTCATGGAACA
R     AGCCTTTTCTACCTCACGCC
111 NM_001163434.1
ERdj3
F     AGGAGCGAAGAGAACTGGACT
R     AAATGACTCCAATCCCCAGCC
116 NM_026400.5
Gabra1
F     ATTCTGAGCACACTGTCGGG
R     TCATAACCGTCCAGCAGTCG
110 NM_010250.5
Appendix III. Murine primers used in real-time PCR analysis
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1Primers(were(designed(to(measure(the(abundance(of(sel61(suppressor(of(lin6126like(protein((Sel1l),(DnaJ heat(shock(
protein(family((Hsp40)(member(C3 (p58IPK),(synovial(apoptosis(inhibitor(1,(synoviolin (Hrd1),(homocysteine6inducible(
endoplasmic(reticulum(stress6inducible,(ubiquitin6like(domain(member(1((Herp),(stress6associated(endoplasmic(
reticulum(protein(1 (RAMP4),(spliced(variant(x6box(binding(protein(1((Xbp1s),(DNA6damage(inducible(transcript(
3(Chop),(Glucose6regulated(protein,(78(kDa (Grp78),(DnaJ heat(shock(protein(family((Hsp40)(member(B11((ERdj3),(
gamma6aminobutyric(acid((GABA)(A(receptor(subunit(alpha61((Gabra1),(36Hydroxy636methylglutaryl6Co(A(reductase(
(Hmgr),(low6density(lipoprotein(receptor((Ldlr),(and(18S(ribosomal(RNA((18S).(
2Primer(sequences(are(shown(in(a(5’(to(3’(orientation.
Hmgcr
F     GTAAGCGCAGTTCCTTCCGC
R     TTGTAGCCTCACAGTCCTTGG
105 NM_008255.2
Ldlr
F     CACTCGCCCAAATTCACCTG
R    ATCCTCACTGTGCTTCGGTG
165 NM_010700.3
18S
F     GTGGGCCTGCGGCTTAAT
R     GCCAGAGTCTCGTTCGTTATC
171 NR_003278 
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Appendix  IV.  Schematic  representation  of  ΔSel1lLiver  mice.  The  black  filled  boxes  represent  
exons.  The  black  circles  with  straight  lines  represent  lox  p  sites  placed  specifically  between  exon  
6.  Genotyping  primers  are  shown  as  thin  black  lines  and  bracket  an  800  bp  region  for  the  WT  
gene  and  a  200  bp  region  for  the  mutated  Sel1l  gene.  	  	  	  	  	  
 	  
WT 
ΔSel1l
Liver 
1 5     6   7    8          12 
1 5     6   7    8          12 
Sel1l  
Alb-­Cre  
